	Total number of participating residents (% of total)	Number of residents with burnout (% of total)	p-value of difference in burnout rate per characteristic

Gender

 Male	96 (40.7)	45 (46.9)

 Female	140 (59,3)	53 (37.9)

			0.17

Years in training

 1	52 (22.2)	22 (42.3)

 2	23 (9.7)	11 (47.8)

 3	31 (13.1)	8 (25.8)

 4	50 (21.2)	24 (48.0)

 5	45 (19.1)	18 (40.0)

 6	25 (10.6)	11 (44.0)

 7	8 (3.4)	2 (25.0)

			0.49

Type of specialty

 Surgical	57 (24.2)	26 (45.6)

 Medical	144 (61.0)	59 (41.0)

 Supportive	34 (14.4)	12 (35.3)

 missing	1 (0.4)

			0.62

Satisfaction with work/life balance

 Very dissatisfied	31 (13.1)	21 (67.7)

 Dissatisfied	4 (1.7)	2 (50.0)

 Neutral	69 (29.2)	14 (20.3)

 Satisfied	130 (55.1)	61 (46.9)

 Very satisfied	2 (0.8)	0 (0.0)

			< 0.001

Quality of life

 As bad as it can be	12 (5.1)	10 (83.3)

 Bad	59 (25.0)	37 (62.7)

 Neutral	79 (33.5)	37 (46.8)

 Good	77 (32.6)	14 (18.2)

 As good as it can be	9 (3.8)	0 (0.0)

			< 0.001

Burned outa	98 (41.5)

 Emotionally exhaustedb	125 (53.0)

 Depersonalizedb	125 (53.0)

 Reduced personal accomplishmentb	60 (23.4)


Prevention level	Goal	Child-protective examples

Zero-order	Prevent the development of a hazard	Urban planning to reduce GHGs from vehicular traffic and increase pedestrian access, resulting in improved air quality and increased physical activity (Sheffield and Galvez 2009)

Primary	Block interaction between hazard and human	Relocation of low-lying island populations facing increased risk of flooding, or distribution of mosquito nets

Secondary	Prevent effects after exposure to the hazard	Activation of early warning systems before heat waves

Tertiary	Reduce morbidity and mortality, avoid complications, and restore function	Postdisaster restoration of chronic care services


Mode	Controlled/Known Parameters	Parameters to Estimate

Calibration	Main measurement parameters	System calibration parameters

Normal estimation	System calibration parameters	Main measurement parameters


Abbreviation	Description, Definition

 	Tissue mapping in specific compartments

ABM	Adipose bone marrow

TV	Total volume of the body (from ankle to wrist), without INF

TVV	Total visceral volume: includes intrathoracic and intraabdominal volume.

TSV	Total somatic volume (TV without TVV).

TLT	Total lean tissue

VLT	Visceral lean tissue: includes lean tissue of intrathoracic and intraabdominal organs.

SLT	Somatic lean tissue: mostly muscles

TAT	Total adipose tissue (without INF)

SAT	Somatic adipose tissue (TAT without VAT)

TAST	Total adipose soft tissue (TAT without ABM)

SAST	Somatic adipose soft tissue (TAT without ABM and VAT)

SCAT	Subcutaneous adipose tissue (SAST without IMAT)

IMAT	Intermuscular adipose tissue (SAST without SCAT)

VAT	Visceral adipose tissue (IAAT + MAT without INF)

IAAT	Intraabdominal adipose tissue: retroperitoneal and intraperitoneal (mesenteric, omental) fat depots (without INF)

MAT	Intrathoracic, mainly mediastinal adipose tissue

INF	(Undigested) intraluminal nutrition fat in the gastrointestinal tract

 	Tissue mapping of body segments

TV-LE	Total volume of lower extremities (apex trochanter major to ankle joint)

TV-TR	Total volume of trunk (acromion to apex of trochanter major)

TV-UE	Total volume of upper extremities (wrist to acromion level)

LT-LE	Lean tissue volume of lower extremities (apex trochanter major to ankle joint)

LT-TR	Lean soft tissue volume of trunk (acromion to apex of trochanter major)

LT-UE	Lean soft tissue volume of upper extremities (wrist to acromion level)

SAST-LE	Adipose soft tissue volume of lower extremities (apex trochanter major to ankle joint)

SAST-TR	Adipose soft tissue volume of trunk (acromion to apex of trochanter major)

SAST-UE	Adipose soft tissue volume of upper extremities (wrist to acromion level)


PSQI components score	Casesn = 314	Controlsn = 102	P value

Subjective sleep quality	1.01 ± 0.77	0.89 ± 0.79	0.127

Sleep latency	0.98 ± 0.89	0.69 ± 0.88	0.001

Sleep duration	0.68 ± 0.79	1.29 ± 0.86	0.000

Habitual sleep efficiency	0.95 ± 1.03	0.25 ± 0.64	0.000

Sleep disorders	1.21 ± 0.69	0.74 ± 0.63	0.000

Use of sleep medications	0.10 ± 0.46	0.01 ± 0.09	0.055

Daytime dysfunction	1.69 ± 0.95	1.63 ± 1.00	0.635

Total	6.62 ± 3.62	5.50 ± 2.51	0.020


Gene/exon	Sequences	Tann

β-globin	Forward primer: 5'-GTGCACCTGACTCCTGAGGAGA-3'Reverse primer: 5'-CCTTGATACCAACCTGCCCAG-3'Probe: 5'-FAM-AAGGTGAACGTGGATGAAGTTGGTGG-RTQ1-3'	60°C

PARK2\ex1	Forward primer: 5'-CAGCGGCTCTCCTGGGTTAAA-3'Reverse primer: 5'-TACGACTCCCAGCAGGCCCT-3'Probe: 5'-ROX-CCTAGGAATGCGCACGCGCGGAG-RTQ1-3'	60°C

PARK2\ex2	Forward primer: 5'-ATCTCAGGCATGAATGTCAGATT-3'Reverse primer: 5'-TGACCAGTTGCGTGTGATTT-3'Probe: 5'-ROX-ATGAGCAATGGAGCTGGCGGCATCC-RTQ1-3'	60°C

PARK2\ex3	Forward primer: 5'-CATTGTGCAGAGACCGTGGAGAA-3'Reverse primer: 5'-GCTGAGGTCCACCCGAGTCAA-3'Probe: 5'-ROX-AAATGAATGCAACTGGAGGCGACGACCC-RTQ1-3'	60°C

PARK2\ex4	Forward primer: 5'-TAGCCACTTCTTCTGCTTTT-3'Reverse primer: 5'-TGCACTGTACCCTGAGTTTT-3'Probe: 5'-ROX-ATTGCAAAGGCCCCTGTCAAAGAGTGCA-RTQ1-3'	60°C

PARK2\ex5	Forward primer: 5'-TCTTGCTGGGATGATGTTTTAATTCCAAA-3'Reverse primer: 5'-TTGCAATAAGAGGAATGAAT-3'Probe: 5'-ROX-AATGCCAATCCCCACACTGCCCTGG-RTQ1-3'	60°C

PARK2\ex6	Forward primer: 5'-CCGTGGAGGGAAGTGACACTAT-3'Reverse primer: 5'-TGCACCTGATCGCAACAAAT-3'Probe: 5'-ROX-TGTGCGCGTAATGCAAGTGATGTTCCG-RTQ1-3'	60°C

PARK2\ex7	Forward primer: 5'-GGGTCGTGAACAAACTGCCGATCATT-3'Reverse primer: 5'-AGGAGCCCCGTCCTGGTTTT-3'Probe: 5'-ROX-AAGCAAATCACGTGGCGGGAGTTGCAC-RTQ1-3'	60°C

PARK2\ex8	Forward primer: 5'-TCACTCACCTGCTCTTCTCCCAGAAT-3'Reverse primer: 5'-CAGAGTGAAAGTGACGTTTT-3'Probe: 5'-ROX-TCAAGGAGTTGGGACAGCCAGCTGTTGG-RTQ1-3'	60°C

PARK2\ex9	Forward primer: 5'-ACCCCACAGCCCAGGCCATT-3'Reverse primer: 5'-TGCAGATGGGGGGCGTGTTA-3'Probe: 5'-ROX-TTCGCAGGTGACTTTCCTCTGGTCAGGC-RTQ1-3'	60°C

PARK2\ex10	Forward primer: 5'-GCTTGGAGGAATGAGTAGGGCATT-3'Reverse primer: 5'-GTTTGCCTTCTGCCGGGAAT-3'Probe: 5'-ROX-AGGCTTCAAATACGGCACTGCACTCCCC-RTQ1-3'	60°C

PARK2\ex11	Forward primer: 5'-TGGTGGTTTTCTTGATGGTTT-3'Reverse primer: 5'-AACGCCTTTCCTCTTTGTTT-3'Probe: 5'-ROX-TCGGCGGCTCTTTCATCGACTCTGTAGG-RTQ1-3'	60°C

PARK2\ex12	Forward primer: 5'-CACGATCTTCCTGAGAAGTCAGACAAT-3'Reverse primer: 5'-ACAACACTGCATGCGGCAAA-3'Probe: 5'-ROX-TCTGCGTAGTGTGGGTAAGAGCATGCGG-RTQ1-3'	60°C


	SCS	CCS	TCS

Log evidence	14084	14072	14058


Cell line	EGFR mutation status	Sulforaphane

IC50 (μM) a

A549	Wild-type	10.2 ± 0.15

CL1-5	Wild-type	9.7 ± 0.33

H3255	L858R b	14.5 ± 0.21

PC9/gef c	Exon 19 del.	7.3 ± 0.25

H1975	L858R/T790M d	5.9 ± 0.18

HFB	Wild-type	65.4 ± 0.29


Gene	Length	Forward Sequence (5′>3′)	Reverse Sequence (5′>3′)

Runx2	250 bp	CCACCACTCACTACCACACG	TCAGCGTCAACACCATCATT

Osterix	373 bp	ACCAGGTCCAGGCAACACACCTAC	GCAGTCGCAGGTAGAACGCCCTGC

BMP2	154 bp	GGGACCCGCTGTCTTCTAGT	TCAACTCAAATTCGCTGAGGAC

Osteocalcin	302 bp	AGACAAGTCCCACACAGCAG	GGCGGTCTTCAAGCCATACT

Bone sialoproiten	312 bp	CTGAAGCAGGTGCAGAAGGA	TCTGACCCTCGTAGCCTTCA

Osteopontin	354 bp	CTGGCAGCTCAGAGGAGAAG	GGACATCGACTGTAGGGACG

ALP	211 bp	TAACACCAACGCTCAGGTCC	GTGGTTCACCCGAGTGGTAG

Smad1	97 bp	ACCTGTGGCTTCCGTCTC	ATCGTGGCTCCTTCGTC

Smad4	145 bp	CAGCACTACCACCTGGACTGGA	CTGGAATGCAAGCTCATTGTGAA

Smad5	197 bp	AAGTAGATTCTGCCTGGGATT	AGACGGTGGTGGGATGG

Smad8	169 bp	ATCCCTGGCAATCTGTA	CCCTGGCTGTCCTGTAA

PARP-1	72 bp	GGAAAGGGATCTACTTTGCCG	TCGGGTCTCCCTGAGATGTG

GAPDH	240 bp	TGATGACATCAAGAAGGTGGTGAAG	TCCTTGGAGGCCATGTAGGCCAT


Characteristics	Number	Percentage

Socio-demographic characteristics

Gender (n = 674)

Male	278	41%

Female	396	59%

Marital status (n = 679)

Married	232	34%

Single	447	65%

Race (n = 685)

Black	160	23%

Indian	143	21%

White	319	47%

Coloured	53	8%

Medical school characteristics

Profession (n = 654)

Medical doctor	544	79%

Dental practitioner	110	16%

Tertiary institution (n = 677)

University of Cape Town	73	11%

University of the Witwatersrand	84	12%

University of KwaZulu-Natal	101	15%

University of Limpopo	55	8%

University of the Free State	64	9%

University of Pretoria	101	15%

University of the Western Cape	64	9%

Stellenbosch University	101	15%

Walter Sisulu University	34	5%

Provincial bursary obligation (versus not) (n = 670)	142	21%

Student loans (versus not) (n = 678)	142	35%


Number of donors	Europe	North America	Australasia and South Africa	Total

<50	7	2	5	14

51–100	2	1	2	5

101–1000	2	0	0	2

>1000	0	2	0	2


Model description	RMSEA	CFI	χ2	df	Δχ2	Δdf	Statistical significance

1. Configural model: no constraints imposed	0.02	0.99	8.06	6	-	-	-

2. Factor loadings: constrained equally across groups	0.03	0.97	45.44	19	37.38	13	p < 0.0005


Before treatment compared to first treatment (PET 1–PET 2)

ACC	Midbrain (+0.45), pallidum (+0.61), putamen (+0.34)

Hippocampus	Amygdala (+0.20), insula (+0.37), pallidum (+0.47)

Insula	Pallidum (+0.56)


	Group OP vs. Group 0T	Group NT vs. Group NP

	T = 4 weeks	T = 8 weeks	T = 4 weeks	T = 8 weeks

Weight	p < 0.01	p < 0.001	p < 0.05	p < 0.01

BMI	NS	NS	NS	NS

Cholesterol	p < 0.001	NS	NS	NS

HDL	NS	p < 0.001	p < 0.05	p < 0.05

LDL	NS	p < 0.01	NS	p < 0.01

Triglycerides	NS	p < 0.001	p < 0.01	p < 0.01

Systolic BP	NS	p < 0.05	p < 0.05	NS

Diastolic BP	p < 0.05	p < 0.001	p < 0.05	p < 0.001

Glucose	p < 0.001	p < 0.001	NS	NS


	Migration of stem	Rotation of stem

	(mm)	(degrees)

x-axis	0.09	0.36

y-axis	0.13	0.76

z-axis	0.23	0.13


Protein name	Accession	Score	Coverage	Peptide	Fold change

Upregulated proteins

Sarcoplasmic calcium-binding protein 1	comp40442_c0_seq1_No.1	83	16.1	3	8.40

Troponin C isoform 2b	comp22592_c0_seq1_No.1	69	26.3	3	2.78

Clip domain serine proteinase 3	comp19522_c0_seq1_No.1	520	33.8	9	2.40

Copine-8	comp20718_c0_seq2_No.1	841	30.9	14	2.19

Slow muscle myosin S1 heavy chain	comp20546_c0_seq16_No.1	2,058	43.7	26	2.13

Putative secreted salivary gland peptide	comp12272_c1_seq1_No.1	83	22	3	2.23

Chloride intracellular Channel isoform 1	comp20820_c0_seq1_No.1	100	25.7	5	2.11

Myophilin	comp18304_c1_seq2_No.1	1,662	62.4	8	2.03

Spermine synthase	comp18763_c0_seq1_No.1	200	16.1	4	2.02

Putative phosphoglycerate kinase	comp12041_c0_seq1_No.1	897	33.5	13	2.02

Downregulated proteins

Sacsin	comp19443_c0_seq1_No.1	42	0.2	1	31.39

Phospholipase D1	comp1157_c0_seq1_No.1	211	17.4	5	6.97

Low-density lipoprotein receptor	comp20609_c0_seq1_No.1	283	10.2	6	5.77

Pseudomonas aeruginosa pathogenicity island I	comp20408_c0_seq1_No.1	54	7.6	1	3.02

pacifastin-like serine protease inhibitor	comp3991_c0_seq1_No.1	82	15.1	2	2.99

Anti-lipopolysaccharide factor 4	comp12264_c0_seq1_No.1	179	27.6	2	2.82

Anti-lipopolysaccharide factor isoform 4	comp20686_c1_seq1_No.1	126	47.7	4	2.12


Gene	% Nucleotide identity	% Amino-acid identity

NP	98.9	99.3

P	98.8	98.4

M	98.5	98.7

G	98.2	98.4

L	99.0	99.8


Test	Method description

Polyacrylamide gel electrophoresis (reducing and non-reducing)	Polyacrylamide gel electrophoresis performed in the presence of sodium dodecyl sulphate (SDS PAGE) under both reducing and non-reducing conditions. Gels were stained using Colloidal Coomassie Blue staining

Size exclusion chromatography	Resolution of aggregated forms from the monomeric form of rFIXFc using high performance liquid chromatography (TSKgelG3000SWXL column)

Coagulation activity	One-stage aPTT method performed in accordance with Pharmacopeia guidelines (USP<32> and Ph.Eur. 2.7.11) with respect to WHO International Standard for Factor IX concentrate

FcRn binding	FcRn competitive binding measured using an amplified luminescent proximity homogenous assay

Activated rFIXFc	Enzyme-linked immunosorbent assay (ELISA) based on the binding of hATIII to activated factor IX for the detection of the activated form of rFIXFc

Bioburden	Microbial enumeration test performed in accordance with Pharmacopeia guidelines (USP<61> and Ph.Eur. 2.6.12)

Endotoxin	Kinetic turbidimetric method in accordance with Pharmacopeia guidelines (USP<85> and Ph. Eur. 2.6.14)


	Mercury measure available	No mercury measure

4+ DAs at start of pregnancy	69.6% (1823)	69.9% (4200)

Visited dentist in pregnancy	86.3% (2464)	86.0% (5765)

Had a new DA in pregnancy	22.4% (633)	25.0% (1632)

Had old DA removed in pregnancy	14.8% (420)	15.7% (1021)

Tooth extraction in pregnancy	3.8% (108)	3.9% (251)


Objectives/Social Values	Option which maximises likelihood of success

Equalise access, outcome	Universal (monopoly) Public Insurance/Financing

Maximise choice; diversity + safety netOptimise the max of these 2 objectives	Pure private (competitive) scheme

Both of the above	Mixed public-private scheme


Condition	Major reported impairments of postural responses	Cortical function during impaired standing postural responses

Stroke involving cortex	Feet-in-place responses: change in the distal-to-proximal muscle pattern and delayed muscle onset as well as delayed and slowed rates of force development in the more severely involved limb (Di Fabio et al., 1986; Ikai et al., 2003)	Unaware of studies utilizing measures of cortical neurophysiology during standing postural responses post-stroke

	Stepping responses: paretic limb exhibits delayed foot-lift, low clearance, need for multiple steps, or an inability to initiate a step (Lakhani et al., 2011; Martinez et al., 2013). Steps are non-paretic limb dominant, even when obstacles block the limb (Lakhani et al., 2011; Mansfield et al., 2012). Impairments associate with increased fall risk and, in contrast, greater use of the paretic limb associates with better recovery (Mansfield et al., 2012, 2013)

Advanced age	Age associates with delays and antagonistic co-contraction of muscles, as well as greater displacement and instability (Halicka et al., 2012)	Electroencephalographic (EEG) PEP delayed, bifid (double-peaked), and decreased with age—effects larger in balance impaired elders (Duckrow et al., 1999)

	Dual task costs greater for elderly only in late-phase in-place and stepping responses, more so for stepping and more so if balance impaired elder (Brown et al., 1999; Rankin et al., 2000; Brauer et al., 2001, 2002; Zettel et al., 2008)

Parkinson's disease	Falls, instability, antagonistic co-contraction and lack of modulation based on knowledge of perturbation. Stepping responses may exhibit freezing or have decreased velocity and step length (Jacobs et al., 2005, 2009b; Jacobs and Horak, 2006; Smith et al., 2012)	Increased desynchronization of EEG beta signal, and this increase associates with decreased response adaptation to perturbation magnitude (Smith et al., 2012)

	With dual tasking, in-place responses are not modulated, and falls increase during stepping responses, but postural preparation or freezing unchanged (de Lima-Pardini et al., 2012; Jacobs et al., 2014a)

Low back pain	Increased pre-perturbation muscle activation, increased activation amplitude at distal muscle, but decreased or delayed trunk muscle activation (Jacobs et al., 2011)	Late positive peak PEP larger with LBP; larger PEP correlates with less postural instability, disability, and fear of activity (Jacobs et al., 2014b)


 	PRE TTS implementation	POST TTS implementation

Missed injuries	Study population (N)	Missed injury rate (%)	Patients with Missed injuries (N)	Study population (N)	Missed injury rate (%)

Enderson, 1990	 	N/A	2.0	37	399	9.27

Vles, 2003	 	 	 	49	3,879	1.26

Hoff, 2004	 	 	 	42	432	9.72

Soundappan, 2004	 	 	 	12	76	15.8

Howard, 2006	 	 	 	12	90	13.3

Okello, 2007	 	 	 	78	403	19.4

Janjua, 2008	 	 	 	134	206	65.0

Ursic, 2009	35	981	3.57	62	1,006	6.16

Huynh, 2010	 	 	 	80	5,143	1.56

Overall	35	981	3.57	506	11,634	4.35


Stress-associated and virulence genes	Protein encoded/function

Oxidative stress

oxyR	DNA-binding transcriptional regulator OxyR

sodA	Manganese-containing superoxide dismutase

soxR	Redox-sensitive transcriptional activator of oxidative stress regulon

General stress

uspA	Universal stress global response regulator

rpoS	Regulator of the general stress response (σS)

Starvation

phoA	Alkaline phosphatase

dps	DNA-binding protein from starved cells

Cold shock

cspA	Cold shock protein A

cspC	Cold shock protein C

cspE	Cold shock protein E

UV

mutS	DNA mismatch repair protein—Mutator S

Acid resistance

gadA	Glutamate decarboxylase A

gadB	Glutamate decarboxylase B

gadW	DNA-binding transcriptional activator GadW

Intimin

eae	Intimin (adherence protein)

Toxin

stx1A	Shiga-like toxin 1 A subunit

stx2A	Shiga-like toxin 2 A subunit

Motility

fliC	Flagellin


Gene	Sequence 5’to 3

MAPK	Forward	CAGTGGGATGGAATTGAAAG

	Reverse	AGCAGAAGGAATGAGTGTGC

NOS1	Forward	GACTGTTGAGATGGAAGAAC

	Reverse	ATCTTCCTGTCTCCGAGGCG

NOS3	Forward	GTGATGGCGAAGCGAGTGAAG

	Reverse	CCGAGCCCGAACACACAGAAC

PIK3CA	Forward	CTCCACGACCATCATCAGG

	Reverse	GATTACGAAGGTATTGGTT


Species	Erroneous sequences	Corrected sequences	Apparent rate of correction (%)

H. sapiens	941	331	35.2

M. musculus	455	106	23.3

R. norvegicus	704	178	25.3

M. domestica	434	93	21.4

G. gallus	458	118	25.8

X. tropicalis	547	176	32.2

D. rerio	1376	180	13.1

F. rubripes	507	97	19.1

B. floridae	1753	46	2.6

C. intestinalis	391	28	7.2

C. elegans	215	49	22.8

D. melanogaster	337	60	17.8


characteristics	C/G/BMSCs-dECM scaffolds	C/G scaffolds

Pore diameter (μm)	289.17 ± 80.28	227.17 ± 44.37

Porosity (%)	89.25 ± 3.75	88.48 ± 2.28

Water uptake ratio	13.81 ± 1.00	11.07 ± 0.87

Compressive modulus (MPa)	0.82 ± 0.07	1.10 ± 0.11


Defense related transcripts Leaf	Stress related transcripts Leaf

EST/mRNA	Fold	Description	EST/mRNA	Fold	Description

EH615198	6.4	Nicotiana tabacum nictaba mRNA (NT1)	TA14956_4097	3.8	Tamarix Putative stress-responsive protein

FG636567	3.8	Nicotiana tabacum mRNA for P-rich protein NtEIG-C29	FG156808	3.6	Nicotiana tabacum 1-D-deoxyxylulose 5-phosphate synthase mRNA (DXS1)

EB433973	2.8	Parsley PcPR1-3 mRNA for pathogenesis-related protein type B	CV016057	2.9	Arabidopsis thaliana cold-regulated 413-plasma membrane 2 mRNA COR413-PM2

S44869	2.4	Nicotiana tabacum Endochitinase A precursor	EB441160	2.9	Solanum lycopersicum dxs2 gene for 1-deoxy-D-xylulose 5-phosphate synthase

X12739	2.1	Nicotiana tabacum Pathogenesis-related protein R major form precursor	EB435759	2.8	Ipomoea nil In04 mRNA for caffeoyl-CoA O-methyltransferase

TA14009_4097	0.5	Nicotiana tabacum Chitinase 134	TA12600_4097	2.8	Solanum tuberosum Low temperature and salt responsive protein

EB425556	0.5	Arabidopsis thaliana beta-1,3-glucanase-related mRNA	EB451519	2.8	Solanum lycopersicum geranylgeranyl pyrophosphate synthase 1 (GGPS1)

EH624302	0.5	Arabidopsis thaliana callose synthase 1 mRNA CALS1	EB445705	2.7	Vitis vinifera RD22-like protein mRNA

Defense related transcripts Flower	DV161729	2.1	Arabidopsis thaliana snf1-related protein kinase 2.2, SNRK2.2

FG167555	3.8	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 111B (ACRE111B) AP2-DOMAIN	FG633784	2.0	Solanum lycopersicum anthocyanin acyltransferase mRNA, Jasmonic acid inducible

AB041516	3.5	Nicotiana tabacum P-rich protein EIG-I30	EB680165	0.3	Arabidopsis thaliana SIP3 (SOS3-INTERACTING PROTEIN 3)

TA14524_4097	3.0	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 65 (ACRE65) mRNA,	EB433693	0.4	Arabidopsis thaliana AFP1 (ABI FIVE BINDING PROTEIN)

FG640154	2.6	Nicotiana tabacum mRNA for basic pathogenesis-related protein Thaumatin	TA14058_4097	0.4	Ipomoea nil CHS-D mRNA for chalcone synthase

FG635113	2.5	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 20 (ACRE20) mRNA; EF-hand calcium binding protein	EB439278	0.4	Nicotiana tabacum NtERD10B mRNA for dehydrin

TA13004_4097	2.2	Nicotiana tabacum mRNA for hin1 gene: Harpin inducing protein	EB437158	0.5	Ricinus communis leuco-anthocyanidin dioxygenase mRNA

TA15227_4097	2.1	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 76; NDR1/HIN1	DW003496	0.5	Ricinus communis Salt-tolerance protein

AB127582	2.1	Nicotiana tabacum Harpin inducing protein 1-like 18 DOMAIN: LEA_2	EB438355	0.5	Arabidopsis thaliana ATHK1 (histidine kinase 1/ osmosensor)

			EB438355	0.5	Catharanthus roseus cold inducible histidine kinase 1 (iK1) mRNA


Province	City	PCR-confirmedP. falciparum(N)

Khyber Pakhtunkhwa	Bannu	39

 	Hangu	19

 	Peshawar	4

 	Thal	29

Punjab	Bhakkar	1

 	Lahore	1

 	Mianwali	28

 	Muzaffarghar	13

 	Rawalpindi	0

Balochistan	Quetta	26

 	Zhob	7

Sindh	Hyderabad	0

 	Karachi	2

Capital	Islamabad	2

Total	 	171


Animal group	Number ofhemispheres used	MaxPs of activation evoked byF and revF stimulation	Comparison between sound types

F	revF	Type of test	p values

Trained	12	0.212 ± 0.063	0.116 ± 0.029	t test	8.74E-05

Naïve	12	0.199 ± 0.060	0.114 ±0.026	t test	1.97E-04


Location	X	Y	Z	Extent	Z-value

Univariate effect of degradation [((NV + SW)/2) > CL]

Left inferior frontal gyrus (p. Opercularis)	−54	10	20	555	3.92

 Left precentral gyrus	−52	8	30		3.86

 Left precentral gyrus	−46	2	28		3.80

Multivariate acoustic form coding

Left posterior STG	−63	−33	15	392	4.94

 Left mid-STG	−57	−12	4		4.62

 Left mid-anterior STG	−54	−6	−4		4.37

Right posterior STG	54	−42	15	254	4.13

 Right anterior STG	57	12	−8		3.99

 Right supramarginal Gyrus	54	−36	26		3.83

Multivariate syllable identity coding

Left mid-posterior left STG	−63	−24	8	303	4.59

 Left mid-STG	−48	−15	0		4.38

 Left posterior STS	−57	−39	8		4.21

Right posterior STG	69	−30	11	172	4.44

 Right posterior STG	57	−27	8		4.19

 Right mid-STG	63	−18	0		3.99

Left precentral gyrus	−51	0	41	83	4.39

 Left postcentral gyrus	−60	−3	38		3.97


Author	Age and sex	Mechanism	Fielding type	Associated injuries	Duration to diagnosis	Reduction method and treatment	Results

Castel et al., 2001 [4]	41 M	Rugby injury	I	(—)	1 month	Reduction and Minerva jacket	Good

Fuentes et al., 2001 [5]	24 M	Suicidal jump	IV	Initial odontoid fracture only	1 month	C1-C2 fusion	Unknown

Kim et al., 2007 [8]	34 M	Fall down from high place	II	Lt superior facet fracture of C2	1 day	C1-C2 fusion	Good

Sinigaglia et al., 2008 [11]	26 F	Road traffic accident	I	(—)	45 days	Reduction and halo vest	Fair; because of cervical stiffness and headache

21 F	Road traffic accident	I	(—)	1 day	Reduction and halo vest	Good

29 M	Road traffic accident	I	(—)	1 day	Reduction and rigid collar	Good

Wang et al., 2008 [14]	44 F	Not described	I	(—)	6 months	Immobilization with halo vest	Poor; because of bilateral hand numbness

Goel et al., 2010 [6]	28 M	Fall down from high place	Not described	Odontoid fracture	1 day	Intraoperative facet manipulation	Good

Singh et al., 2009 [10]	25 F	Road traffic accident	I	(—)	0 day	Skull traction and halo brace	Good

Jeon et al., 2009 [7]	25 F	Road traffic accident	I	Thoracic fractures, alar ligament injury	5 days	Immobilization with Philadelphia brace	Good

Stenson, 2011 [12]	31 F	Falling backward	I	(—)	0 day	Immobilization with hard collar	Good

Marti et al., 2011 [9]	24 F	Stretching neck herself	I	(—)	1 day	Reduction and halo vest	Good

Venkatesan et al., 2012 [13]	20 F	Road traffic accident	I	(—)	0 day	Skull traction and hard collar	Fair; because of occipital pain

52 F	Road traffic accident	I	(—)	0 day	Halo traction and hard collar	Fair; because of occipital pain


Filter type	Central Frequency,f0	Rotation Variation Parameter,c	Half Central Bandwidth, bw	Number of Comb Teeth,n

Comblet filter: BSF	127.178 Hz	2%	1.272 Hz	100

Comblet filter: BPFI	308.242 Hz	2%	3.082 Hz	41

Comblet filter: BPFO	171.758 Hz	2%	1.718 Hz	74

Comblet filter: FTF	28.626 Hz	2%	0.286 Hz	447


S/N	Demographic characteristics	No of cases	Percentage	Chi square test	P Value

1	Age:a. up to 20 yearsb. 21-40 yearsc. 41 years and above	3417	5.8880.3913.75	79.411737.686253.6862

2	Parity:a. Para 0-1b. 2-4c. 5 and above	61629	11.7631.3756.86	59.647014.15681.9215	0.050.5

3	Booking Status:a. Bookedb. unbooked	1338	25.4974.50	24.5101	0.001

4	Referral status:a. Referred from other placesb. within hospital	3912	76.4723.52	28.5882	0.001

5	Level of medical person dealing:a. Paramedics LHV/Nursesb. medical officerc. resident doctord. senior resident	211893	41.1735.2917.645.88	3.17648.823542.705879.4111	 0.5 0.5


Patient Group	P53 expression	χ2	P value

(No. of cases)	(+)	(-)

Grade I (14)	0	14	6.568	0.037

Grade II (10)	2	8

Grade III (16)	6	10


Plant Age (Weeks)	Free PAA pmol (g FW)−1	Free IAA pmol (g FW)−1

Two weeks	98 ± 6.4	35 ± 2.7

Six weeks	23 ± 2	15 ± 1


Misclassification cost setting 5:1, post-pruning confidence 1%

	Classified as

Observed	SN	Non-SN

SN	0	34

Non-SN	0	815

Misclassification cost setting 10:1, post-pruning confidence 1%

	Classified as

Observed	SN	Non-SN

SN	8	26

Non-SN	66	749

Misclassification cost setting 25:1, post-pruning confidence 50%

	Classified as

Observed	SN	Non-SN

SN	31	3

Non-SN	18	797


Reference	Type of study	Subjects/number of studies	Results

Knutson et al. (72)	Cohort study and longitudinal, blood pressure and actigraphic sleep measured at 5-year intervals	578 AA and White	Reduced sleep predicted higher BP and adverse change in BP; sleep duration appeared to mediate racial differences in diastolic BP

Knutson (54)	National surveys, self-report	8 surveys conducted over 31 years	AAs consistently more likely to report short sleep duration than any other racial group

Vishnu et al. (73)	Cross-sectional survey, self-report	369,217 multi-ethnic US subjects	Strongest correlation between insufficient sleep and CHD found in AAs

Ruiters et al. (66)	Meta-analysis, variable methods including subjective and objective measures of sleep	14 studies	AAs had poorer sleep continuity and duration, less slow wave sleep, and a greater proportion of stage 2 sleep

Jean-Louis et al. (74)	National Health Interview Survey, 1977–2009, cross-sectional, face to face interviews	All ethnicities surveyed but restricted to Black and White participants	Among Black, very short sleepers 76% increased risk of overweight and 81% increased risk of obese

Halder et al. (68)	Cohort study using PSQI and in home polysomnography, correlation with % African genetic ancestry	70 AA and 101 European-American	% African ancestry correlated with lower percentage slow wave sleep but not sleep duration or efficiency

Curtis et al. (63)	Cross-sectional, actigraphic sleep	426 Midwestern US adults with oversampling of AAs	AA obtained less sleep and had lower sleep efficiency. Sleep duration predicted 41% of cardiometabolic risk factor variance

Johnson et al. (67)	Cross-sectional analysis, self-report	5,301 AAs in the Jackson Heart Study	54% reported <6 h sleep, 5% >9 h sleep. Social and environmental characteristics associated with sleep duration

Riestra et al. (70)	Cross-sectional analysis	2,962 AA participants	A SNP in the CLOCK gene associated with sleep duration after multifactorial adjustments


 	Interest learning MBP (%)	Interest in participating in study of MBP during MHD (%)

Total (n = 89)	70	74

Age (years)

 18–34	100	100

 35–49	54	69

 50–64	71	74

 65–79	78	78

 ≥80 	46	46

Gender

 Female	74	74

 Males	66	75

Race

 White	54	65

 Black	76	74

 Other	71	100

Dialysis Vintage (years)

 <1	75	79

 1–4	68	74

 5–9	78	89

 ≥10	50	50

Ever used CAM use

 No	62	54

 Yes	74	87


Processing procedure	P(%)	R(%)	F(%)

(1): only candidate drugs replaced	75.9	68.7	71.5

(2): basic processing	77.5	72.3	74.8

(3): (2) + Following anaphora	76.9	76.5	76.7

(4): (3) + Pruned Sentences	78.4	76.2	77.3


	ASA Respondents (n = 209)	ESA Respondents (n = 165)

Answer Options	Response Percent	Response Percent

Blood pressure	88.5%	77.6%

Urine output	83.3%	77.0%

Clinical experience	77.5%	64.8%

Central venous pressure	70.8%	64.2%

Cardiac output	49.3%	53.3%

Pulse Pressure Variation or Systolic Pressure Variation	45.0%	55.8%

Transesophageal echocardiography	43.5%	28.5%

Pulmonary capillary wedge pressure	38.8%	24.2%

Plethysmographic Waveform Variation	25.4%	25.5%

Stroke Volume Variation	19.1%	36.4%

Mixed venous saturation (ScvO2)	18.7%	21.8%

Global end diastolic volume	10.5%	17.0%

Central venous saturation (SvO2)	10.0%	34.5%


	A MSC	BM MSC	COMMON

INHIBITION OF MMP	A2M, MMP2, TIMP1, TIMP2	A2M, MMP2, TIMP2	A2M, MMP2, TIMP2

EPITHELIAL ADHERENS JUNCTION	ACTN1, ACTN4, ACTR2, MYH9, TUBA1C, TUBB, VCL	ACTN1, ACTN4, ACTR2, ARPC3, IQGAP1, MYH9, TUBB, VCL	ACTN1, ACTN4, ACTR2, MYH9, TUBB, VCL

REMODELING OF EPITHELIAL ADHERENS JUNCTION	ACTN1, ACTN4, ACTR2, TUBA1C, TUBB, VCL	ACTN1, ACTN4, ACTR2, IQGAP1, NME1, TUBB, VCL	ACTNI, ACTN4, ACTR2, TUBB, VCL

GERM CELL SERTOLI JUNCTION	A2M, ACTN1, ACTN4, TUB1AC, TUBB, VCL	A2M, ACTN1, ACTN4, CFL1, IQGAP1, TUBB, VCL	A2M, ACTN1, ACTN4, TUBB, VCL

ACTIN CYTOSKELETON	ACTN1, ACTN4, ACTR2, EZR, MSN, MYH9, PFN1, TLN1, VCL	ACTN1, ACTN4, ARPC3, CFL1, FN1, IQGAP1, MSN, PFN1, RDX, VCL	ACTN1, ACTN4, MSN, PFN1, VCL

HEPATIC FIBROSIS	A2M, COL1A1, COL1A2, COL3A1, COL6A2, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP1, TIMP2	A2M, COL1A1, COL1A2, COL3A1, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP2	A2M, COL1A1, COL1A2, COL3A1, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP2

PROTEIN UBIQUITINATION	HSP90AA1, HSP90AB1, HSP90B1, HSPA5, HSPA8, HSPB1, HSPD1, PSMA1, PSMA3, PSMA5, PSMA6	HSP90AA1, HSP90AB1, HSP90B1, HSPA4, HSPA5, HSPA8, HSPB1, HSPD1, PSMA5, PSMB1, PSMB4, PSMB5, PSMB6	HSP90AA1, HSP90AB1, HSP90B1, HSPA8, HSPD1, PSMA5

RHOA SIGNALING	ACTR2, EZR, MSN, PFN1	ACRT2, ARPC3, CFL1, MSN, PFN1	ACTR2, MSN, PFN1

LEUCOCYTE EXTRAVASATION	ACTN1, ACTN4, EZR, GNAI2, MMP2, MSN, TIMP1, TIMP2, VCL	ACTN1, ACTN4, MMP2, MSN, RDX, TIMP2, VCL	ACTN1, ACTN4, MMP2, MSN, TIMP2, VCL


Parameters	Case report [2]	Case report [3]	Our case report

Age	76 years	55 years	55 years

Circumcision	Uncircumcised	Delayed circumcision	Infantile circumcision

Site of stricture	Bulbar urethral stricture	Bulbar urethral stricture	Penile and bulbar urethral strictures

Time to develop malignancy	4 months	3 months	5 years

Presentation	Ulcerative lesion at glans penis	Penile periurethral mass	Ventral penile masses involving glans and whole exteriorised urethra, with associated scrotal wall changes

Treatment	Partial penectomy	Total penectomy	Total penectomy


Area	Bjørndalen	Sverdrup

Samples	Bd1	Bd2	Bd3	Bd4	Sv1, Sv2

Type	Spring water	Thaw water	Mix upstream	Mix downstream	Mat and sediment

pH	2.8	6.2	3.5	3.8	2.3

°C (water)	9	7	7	7	4

°C (air)	6	6	6	6	4

Na	3.1	2.5	3	2.8	42

K	1.1	0.5	1.6	1.3	0.2

Zn	0.3	Na	0.1	0.07	5.1

Ni	0.1	Na	0.03	0.02	1.3

Mg	5.4	1.3	2.6	2.3	145

Ca	Na	Na	Na	Na	10

Mn	0.4	Na	0.2	0.1	9.7

Cu	0.03	Na	Na	Na	0.8

Al	3.4	Na	1.8	0.9	76

Fe total	15	Na	2	2	883

Fe2+	9	Na	1	1	183

Fe3+	6	Na	1	1	700

SO42−	110	10	54	32	1543


	Total types	Total tokens	TTR

Proper nouns (Sem1)	699	9,516	0.073

Basic level count nouns (Sem2)	2,675	25,369	0.105

Basic level mass nouns (Sem3)	288	2,655	0.108

Action words (Sem4a)	228	1,419	0.161

Non-basic level words (Sem4b)	1,507	12,618	0.119


	N	%

Mean Age = 37.5 (S.D.11)

Citizenship

 Greek	77	76.2

 Other	24	23.8

Marital status

 Unmarried	53	52.5

 Married	19	18.8

 Divorced	21	20.8

 Widow	8	7.9

Children

 Yes	62	61.4

 No	39	38.6

Occupation before detention

 Employee	59	58.4

 Student	2	2.0

 Unemployed	26	25.7

 Pensioner	3	3.0

 Housework	9	8.9

 Other	2	2.0

Education level

 Compulsory	36	35.6

 Secondary	32	31.7

 Tertiary	24	23.8

 Postgraduate	9	8.9


Category	Clinical attachment level (CAL)	Probing pocket depth (PD)

Severe periodontitis	≥ 2 interdental sites with CAL ≥ 6 mm (not on same tooth) and	≥ 1 interdental site with PD ≥ 5 mm

Moderate periodontitis	≥ 2 interdental sites with CAL ≥ 4 mm (not on same tooth) or	≥ 2 interdental sites with PD ≥ 5 mm (not on same tooth)

No-or-mild periodontitis	Neither “moderate” nor “severe” periodontitis


Target	Accession Number	Forward Primer	Reverse Primer

Cyp2a4	NM_009997	GGAAGACGAACGGTGCTTTC	CCCGAAGACGATTGAGCTAATG

Cyp3a11	NM_007818	CGCCTCTCCTTGCTGTCACA	CTTTGCCTTCTGCCTCAAGT

Cyp2c37	NM_010001	ATACTCTATATTTGGGCAGG	GTTCCTCCACAAGGCAAC

Cyp2c39	NM_010003	GGAGACAGAGCTGTGGC	TAAAAACAATGCCAAGGCCG

Cyp2d22	NM_019823	GGGCCTTTGTTACCATGTTGG	TACTCGGCGCTGCACATCTG

β-actin	NM_007393	TGTTACCAACTGGGACGACA	GGGGTGTTGAAGGTCTCAAA


Surveillance site	Diarrhoea cases	Total

Non-diarrhoea cases	Rotavirusdiarrhoea	Cholera	Non-rotavirus and non-cholera diarrhoea

No.	%	No.	%	No.	%	No.	%

Bakerganj	163	63.7	31	12.1	27	10.5	35	13.7	256

Mathbaria	163	60.0	38	14.0	23	8.5	48	17.7	272

Total	326	61.7	69	13.1	50	9.5	83	15.7	528


	Total	Male sex	Female sex

Normouricemia (n = 1749)	Hyperuricemia (n = 393)	Normouricemia (n = 954)	Hyperuricemia (n = 238)	Normouricemia (n = 795)	Hyperuricemia (n = 155)

At 1-year

CAD	15	5	10	3	5	2

Congestive heart failure	4	2	2	1	2	1

Stroke	6	2	3	1	3	1

Peripheral vascular disease	0	1	0	0	0	1

At 2-year

CAD	25	8	16	5	9	3

Congestive heart failure	6	3	3	2	3	1

Stroke	11	2	6	1	5	1

Peripheral vascular disease	2	2	1	1	1	1

At 3-year

CAD	31	13	18	8	13	5

Congestive heart failure	15	5	9	3	6	2

Stroke	13	6	8	4	5	2

peripheral vascular disease	8	3	5	2	3	1

At 4-year

CAD	39	16	22	9	17	6

Congestive heart failure	16	6	10	4	6	2

Stroke	18	9	11	6	7	3

Peripheral vascular disease	11	5	7	4	4	1

At 5-year

CAD	44	17	26	11	18	7

Congestive heart failure	21	7	13	5	8	2

Stroke	23	13	13	8	10	5

Peripheral vascular disease	12	6	7	4	5	2

Cumulative Numbers of major CVD events over 5 years

CAD	154 (8.8%)	59 (15.0%)	92 (9.7 %)	36 (15.1%)	62 (7.8%)	23 (14.8%)

Congestive heart failure	62 (3.6%)	23 (5.9%)	37 (3.9%)	15 (6.1%)	25 (3.2%)	8 (5.2%)

Stroke	73 (4.2%)	32 (8.1%)	41 (4.3%)	20 (8.2%)	30 (3.8%)	12 (7.7%)

Peripheral vascular disease	33 (1.9%)	17 (4.6%)	20 (2.1%)	11 (4.6%)	13 (1.6%)	6 (3.7%)


	ASD (n = 24)	Controls (n = 18)	Statistics

Age	40.54 ± 10.279	37.17 ± 10.983	p = 0.313

Intelligence quotient	114.29 ± 15.213	113.00 ± 13.920	p = 0.779

Gender	12 m:12 f	8 m:10 f	p = 0.721

Nicotine	2.292 ± 5.894	2.222 ± 6.691	p = 0.972

Autism-spectrum quotient	39.08 ± 6.386	12.94 ± 5.504	p < 0.001

Empathy quotient	17.38 ± 9.523	47.94 ± 9.710	p < 0.001

Wender Utah Rating Scale	33.75 ± 16.690	8.72 ± 7.954	p < 0.001

Beck Depression Inventory score	17.25 ± 12.365	3.22 ± 4.236	p < 0.001

Level of education	Low school degree, 1 (4.2%)	Low school degree, 0 (0%)

Medium school degree, 3 (12.5%)	Medium school degree, 3 (16.7%)

High school degree, 9 (37.5%)	High school degree, 6 (33.3%)

University degree, 9 (37.5%)	University degree, 9 (50%)

Other, 2 (8.3%)	Other, 0 (0%)

Occupational situation	Full-time employed, 13 (54.2%)	Full-time employed, 7 (38.9%)

Part-time employment, 4 (16.7%)	Part-time employment, 4 (22.2%)

In vocational training/studying, 1 (4.2%)	In vocational training/studying, 7 (38.9%)

Pension, 1 (4.2%)	Pension, 0 (0%)

Unemployed, 4 (16.7%)	Unemployed, 0 (0%)

Other, 1 (4.2%)	Other, 0 (0%)

Psychiatric medication (in the last 3 months)	No, 11	No, 18

AD, 6	AD, 0

NL, 1	NL, 0

AD + NL, 5	AD + NL, 0

AD + MPH, 1	AD + MPH, 0


Cytological diagnosis	Frequency (n)	Percentage (%)

Chronic granulomatous inflammation	20	27.0%

Chronic sialadenitis	25	33.7%

Acute on chronic sialdenitis	22	29.7%

Benign cystic lesion	7	9.4%

Total	74	39.5%


Plasmid	Properties	Source/Reference

pRS316	Yeast centromeric plasmid. URA3 marker.	[52]

pRS316[PPHO84-GFP-TPHO84] (pRUL1336)	pRS316 containing the PHO84 promoter (600 bp), GFP and the PHO84 terminator (436 bp)	This study

pRS316[PCYC1-GFP-TCYC1] (pRUL1339)	pRS316 containing the CYC1 promoter (300 bp), GFP and the CYC1 terminator (220 bp)	This study

pRS316[PSPL2-GFP-TSPL2] (pRUL1354)	pRS316 containing the SPL2 promoter (647 bp), GFP and the SPL2 terminator (324 bp)	This study

pUG6	Plasmid containing the KAN.MX casette for gene disruptions	[53]

pUG36	Centromeric plasmid to make N-terminal GFP fusions.	Güldener and Hegemann, unpublished

pRS305	Yeast integration plasmid. LEU2 marker.	[52]

pRS305[PPHO84-GFP-TPHO84] (pRUL1359)	pRS305 containing the PHO84 promoter (600 bp), GFP and the PHO84 terminator (436 bp)	This study

pRS305[PCYC1-GFP-TCYC1] (pRUL1360)	pRS305 containing the CYC1 promoter (300 bp), GFP and the CYC1 terminator (220 bp)	This study

pRS313	Yeast centromeric plasmid. HIS3 selection marker.	[52]

pRS313[PHO4](pRUL1334)	pRS313 containing PHO4	[7]

pRS313[BMH1] (pRUL1330)	pRS313 containing a 3.2 kb genomic DNA fragment with BMH1	I.G. Anemaet, unpublished results

pRS305[PHO4] (pRUL1358)	pRS305 containing PHO4	This study

YCplac33	Yeast centromeric plasmid. URA3 marker	[54]

YCplac33[BMH1]	YCplac33 with a 3.2 kb genomic DNA fragment with BMH1	[55]


	N	%

Clinic location

 Rural	18	60

 Urban	5	17

 Peri-urban	7	23

Clinic type

 Quaternary/tertiary	1	3

 Secondary	1	3

 Primary	28	93

Public/private

 Public	27	90

 Private	0	0

 Mixed	3	10

NGO support

 None	17	57

 One	5	17

 Multiple	8	26

Year of pMTCT initiation

 Before 2005	5	17

 Between 2006 and 2008	21	70

 After 2008	4	13

Other characteristics	Mean	Median

 Distance to reference laboratory (km)	22	16

 Catchment population (people)	27,774	19,644

 No. 1st ANC visits in the last 6 months	674	468

 No. institutional births in the last 6 months	482	257

 No. post-partum visits in the last 6 months	418	189


Profession	Round 1	Round 2	Round 3

P-HEMS doctors	21	16	15

P-HEMS nurses	14	12	12

EMS nurses	28	27	26

Dispatch centre operators	14	12	11

Trauma surgeons	22	24	21

Total respondents	83	79	71


		Hierarchical clustering	CCA	TribeMCL	Spectral clustering

Cluster count	Significant	243	243	245	235

	All	293	307	332	308

	Ratio	0.829	0.792	0.738	0.763

Total cluster size	Significant	1,166	1,858	3,600	4,863

	All	1,396	2,144	4,047	5,380

	Ratio	0.835	0.866	0.889	0.903


Primer name	Primer sequence (5′–3′)

Block-E1	CTACAAATCTTGTTACGCGGTATTA

argX-hisR 5′ intergenic region	CAGCTCAAGCGCCGGGACTA

argX-hisR centre intergenic region	TATTACTACCACCGCAGC

Block-E2	TTGTCACAACTTCTAATAA

Block-E3	TTTTAGTTCAATTCTTTAAAGTCG

Block-E4	AATACTGCTTTTTGAATTTTTAG


Year Post Op	Glenoid Loosening	Bearing failure	Infection	Dislocation

1	0	0	0	0

2	0	1	0	0

3	0	0	0	1

4	0	0	0	0

Total	0	1	0	1


WHO region	ILO LABORSTA (farm worker average wage)	World Bank (average value per agricultural worker)	ILO (minimum wage)	US State Department (minimum wage)	Overall average – maximum of sourcesa	Overall average – minimum of sourcesa

AMRO	$6.90	$27.36	$5.27	$5.17	$27.36	$5.11

AFRO	$1.92	$8.18	$2.06	$2.16	$9.05	$1.01

EMRO	$4.84	$18.26	$3.19	$5.00	$18.26	$3.00

WPRO	$5.36	$9.06	$6.81	$6.74	$10.70	$4.98

SEARO	$1.80	$3.47	$1.77	$3.75	$4.04	$1.47

Average	$2.02	$5.10	$2.10	$3.42	$5.84	$1.50


Subject	Gender	Age (yrs)	Etiology	Deafness (yrs)	CI side	CI experience (mos)	CVC (Ph%)	Implant

S1	Male	60	Familial	46	Left	160	93	Clarion CII

S2	Male	51	Progressive	25	Right	124	76	HiRes 90K

S3	Female	74	Familial	22	Left	114	93	HiRes 90K

S4	Male	58	Unknown	11	Right	31	93	HiRes 90K

S5	Male	67	Familial	67	Right	96	86	HiRes 90K

S6	Male	57	Familial	45	Right	174	96	Clarion CII

S7	Female	67	Meningitis	6	Left + right	73	88	HiRes 90K

S8	Female	43	Meningitis	5	Left + right	59	95	HiRes 90K

S9	Female	66	Unknown	35	Right	105	84	HiRes 90K

S10	Female	59	Type II Usher	4	Right	46	89	HiRes 90K

S11	Female	65	Meniere	25	Right	149	92	Clarion CII


Item	Strongly Agree/Agree	QPCCC Subscale

	n	% 1 (95% CIs)

The staff at the hospital showed respect for me	191	91.0 (87.1–94.8)	Respectful communication

The staff at the hospital talked to me in a way I could understand	188	90.8 (86.9–94.8)	Respectful communication

The staff at the hospital showed respect for my family or friends	183	87.6 (83.1–92.0)	Respectful communication

The staff at the hospital gave me information about cancer that was easy to understand	183	87.1 (82.6–91.7)	Cancer information

The staff at the hospital gave me information about cancer and treatments to take home (e.g., booklets, websites)	180	86.1 (81.4–90.8)	Cancer information

During my treatment, staff at the hospital made sure I received the treatment I was meant to have	182	85.8 (81.2–90.5)	Treatment delivery

The doctors at the hospital explained to me the short-term side effects of each treatment option	175	84.5 (79.6–89.5)	Treatment decision-making

The doctors at the hospital explained to me all of the treatments I could have	175	83.7 (78.7–88.7)	Treatment decision-making

During my treatment, staff at the hospital had up-to-date information about my cancer care	173	83.2 (78.1–88.3)	Treatment delivery

During my treatment, staff at the hospital made sure I received treatment that was based on scientific knowledge	169	82.0 (76.8–87.3)	Treatment delivery

During my treatment, staff at the hospital gave me consistent information about my treatment	169	80.9 (75.5–86.2)	Treatment delivery

During my treatment, staff at the hospital co-ordinated my appointments so that I did not have to go to hospital more than necessary	168	80.0 (74.6–85.4)	Treatment delivery


	Name	Screening	Intervention	Follow-up

	Duration	12 months	6 months	6 months

Visits	Time		Surgery	Days 1–3	Wk 2	Wk 4	Wk 8	Wk 12	Wk 16	Wk 20	Wk 24	Wk 48

Anamnesis	Anamnesis	X									X	X

Body weight	X			X	X	X	X	X	X	X	X

Anthropometry	X				X	X	X	X	X	X	X

Dietary assessment, BDI	X				X		X			X	X

Bone density	DEXA	X									X	X

Liver and microbiota	FibroScan and CAPTM	X				X		X			X	X

Stool samples	X				X		X			X	X

Biopsies	Liver, SAT, VAT		X

Supplementation	Loading dose			X	X	X

Maintenance dose					X	X	X	X	X	X	X

Blood parameter	Vitamin D	X			X	X	X	X	X	X	X	X

Biochemical	X			X	X	X	X	X	X	X	X

Liver	X				X		X			X	X

Inflammation	X			X	X	X	X	X	X	X	X

Insulin resistance	X			X	X	X	X	X	X	X	X

Bone turnover	X				X		X			X	X


Drug category	Drug name	Prescribed acutely	Prescribed on discharge

No.	%	No.	%

Antiplatelet drugs	Aspirin	521	37.0	670	47.7

Clopidogrel	50	3.6	66	4.7

Dipyridamole	< 10	< 1	13	0.9

Aggrenox	< 10	< 1	12	0.9

Fibrinolytic	Alteplase	< 10	< 1	n/a

Anticoagulants	Warfarin	16	1.1	49	3.5

Heparin (subcutaneous)	333	23.7	n/a

Heparin (low molecular weight)	44	3.1	32	2.3

Statins	Simvastatin, Atorvastatin	304	21.6	681	48.4


Plant extracts	IC50 values (μg/mL) ± SD	Vitamin C equivalents for a 200 mg capsule (in g)

(1) Rosmarinus officinalis (McConnell's Blue)	3.48 ± 0.22	0.351

(2) Rosmarinus officinalis (Tuscan Blue)	10.84 ± 0.12	1.09

(3) Lavandula-x-intermedia (Margaret Roberts)	138.5 ± 4.0	14.0

(4) Lavandula spica 	125.5 ± 1.8	12.67

(5) Origanum vulgare 	26.43 ± 1.58	2.67

(6) Petroselinum crispum 	53.3 ± 2.63	5.38

(7) Laurus nobilis 	30.85 ± 0.48	3.12

(8) Thymus vulgaris 	36.13 ± 0.85	3.65

(9) Foeniculum vulgaris 	38.36 ± 0.76	3.88

(10) Capsicum annuum (Paprika)	63.06 ± 1.91	6.27

(11) Vitamin Ca	1.98 ± 0.01	—


Item	Number of Patients	Percentage (%)

Gender	Male	127	59.1

Female	88	40.9

Age	<60	108	50.2

≥60	107	49.8

Smoking history	Yes	95	44.2

No	120	55.8

Disease staging	Stage IIIB	36	16.7

Stage IV	179	83.3

Therapy received	Chemotherapy	181	84.2

EGFR-TKI treatment	114	53.0


Namea	Age	Regular medication prior to trial	Trial completion	Result of trial	Treatment decision

Standard vs heat retaining knee support – trials commencing December 2001 to February 2002

Ann	67	solpadol, meloxicam, amitryptiline	Completed	Heat retaining support beneficial	Continued use of heat retaining support

Mel	54	dihydrocodeine, co-dydramol, amitryptiline	Withdrew after 6 weeks – intolerance to supports	No further use of supports

Amber	49	no regular medication, occasional paracetamol	Completed	Heat retaining support beneficial	Continued use of heat retaining support

Lyn	54	rofecoxib, dihydrocodeine, paracetamol	Completed	No benefit from either support	No further use of supports

Pansyb	51	rofecoxib	Completed	No benefit from either support	No further use of supports

Diclofenac vs paracetamol – trials commencing September 2003 to October 2003

Pansyb	53	Rofecoxib	Withdrew after 6 weeks – diclofenac side-effect (stomach pains)	Returned to previous treatment

Rosie	31	Paracetamol	Withdrew after 2 weeks – diclofenac side-effect (mouth ulcers)	Returned to previous treatment

Jack	59	no regular medication	Completed	No benefit from either drug	No regular medication (paracetamol when necessary)

George	61	cod liver oil only	Completed	Diclofenac superior	Continued with diclofenac


Skin cancer	TGF-β	uPA/uPAR

BCC	−/+	?

SCC	++	++

Melanoma	−/+	++


Motif family	Heart	Sperm

E2F1	Hypo-methylated	Hypo-methylated

NFY1	Hypo-methylated	Hypo-methylated

YY11	Hypo-methylated	Hypo-methylated

MYCMAX1	Hypo-methylated	Hyper-methylated

NFKB1	Hypo-methylated	Hyper-methylated

AP1	Hypo-methylated	Hyper-methylated

NRSF2	Hypo-methylated	Neutral

SREBP3	Hypo-methylated	Neutral

SRF2	Hypo-methylated	Neutral

STAT4	Hypo-methylated	Neutral

TCF1	Hypo-methylated	Neutral

GATA1	Neutral	Hyper-methylated

NFE21	Neutral	Neutral

OCT5	Neutral	Neutral

SOX5	Neutral	Neutral

EP3005	Neutral	Neutral

TP536	Neutral	Neutral


 	Features or characteristics	Total

Diagnosed with infection in pregnancy	Infant with CRI but no CRS features at birth	3

Infant with CRI resulting in CRS	5

Diagnosed after birth	Infant with CRI resulting in CRS	7

Acquisition of rubella infection	Maternal infection acquired abroad	8

Maternal infection UK acquired	6

Place of infection not known	1

Maternal place of birth	Mother born abroad	14

Maternal place of birth not known	1

Reported features of 11 of 12 CRS casesb (more than one feature may be reported for each infant)	Thrombocytopaenia at birth	2

Sensorineural hearing loss	10

Eye defects	8

Failure to thrive	3

Heart defects	10

Developmental problems	3

Microcephaly	5


Extraction methods	Abbreviation	Crude extract (mg/g herb)

Heat reflux extraction using water	HRE-W	297.4 ± 28.4

Microwave-assisted extraction using water	MAE-W	390.8 ± 16.6***

Ultrasonic extraction using ethanol (70 % vol/vol)	UE-E	327.4 ± 19.4

Ultrasonic extraction using water	UE-W	275.0 ± 9.0


Treatment	S. aureus NCTC 13297	P. aeruginosa NCTC 10781	Co-culture

	Concentration	Mean OD	Biofilm	Concentration	Mean OD	Biofilm	Concentration	Mean OD	Biofilm

Bacteria		0.1	Moderate		0.54	Strong		0.14	Moderate

BgAg	0.625%	0.04	Non-adherent	0.625%	0.08	Weak	0.625%	0.06	Weak

	0.15%	0.1	Moderate	0.15%	0.23	Strong	0.15%	0.09	Moderate

Bg	0.625%	0.11	Moderate	0.625%	0.07	Weak	0.625%	0.09	Moderate

	0.15%	0.1	Moderate	0.15%	0.5	Strong	0.15%	0.11	Moderate


Source of variations	Degree of freedom	Mean square

pH	Exchangeable acidity	Exchangeable Al	Exchangeable Fe	Exchangeable Ca

Treatments	4	3.71∗	0.23∗	0.08∗	9.03∗	70.70∗

Time 	2	0.65∗	0.15∗	0.01∗	0.37∗	0.52∗

Treatments ∗ time	8	0.76∗	0.34∗	0.01∗	0.14∗	0.24∗

Error	30


EC identifier	Enzyme name	Pathway	Reference

2.1.3.3	Ornithine carbamoyltransferase	Arginine/Proline	Cook et al (2007)

2.3.1.57	Diamine N-acetyltransferase	Polyamines	Cook et al (2007)

2.6.99.2	Pyridoxine 5-phosphate synthase	Misc	Muller and Kappes (2007)

2.7.2.2	Carbamate kinase	Pyrimidine	Cook et al (2007)

3.5.3.6	Arginine deaminase	Arginine/Proline	Cook et al (2007)

3.5.4.2	Adenine deaminase	Purine	Chaudhary et al (2004)

4.2.1.60	3-Hydroxydecanoyl-[acp] dehydratase	Fatty-acid synthesis	Dautu et al (2008)

4.2.1.61	3-Hydroxydecanoyl-[acp] dehydratase	Fatty-acid synthesis	Dautu et al (2008)

4.2.1.75	Uroporphyrinogen-III synthase	Porphyrin	Seeber et al (2008)

4.2.1.99	2-Methylisocitrate dehydratase	MC cycle	Seeber et al (2008)

5.5.1.4	Inositol-3-phosphate synthase	Phospholipid	Smith et al (2007)


Meeting/ Event (Date)	Alcohol industry	Tobacco industry

Informal Discussion meeting for Chairmen & Directors of Large Organisations held at BAT offices (1966)	Courage, Barclay Simmonds	BAT, Gallaher

Practical Skills of Managing People (1981)	Allied, Bass, Charrington, S&N	BAT

Practical Skills of Managing Event (1981)	Allied, Bass-Charrington, Scottish & Newcastle	BAT

Fermenters Symposium (1982)	Allied, Watney, Grand Met	BAT

CBI Conference, Seminar: Employee Involvement (1983)	Allied, Bass, Brewers’ Society, Grand Met, Lyons Tetley, Truman, Whitbread	BAT

Institute of Chemical Engineers (ICHEME) Meeting (1985)	Guinness, Watney, Nabisco	BAT

Minerva Public Relations Group UK Meeting (1988)	The Alcohol Duty Group	The Tobacco Duty Free Group

Statistics for Industry Ltd., Statistical Workshops (1991)	Allied, Bass, Guinness	Imperial, Rothmans

Advertising Association- Performance Monitoring Seminar (1994)	Carlsberg-Tetley, Allied-Lyons, Hiram Walker Group, United Distillers	BAT

Monitoring Advertising Performance Event (1998)	Guinness, Scottish Courage, IDV	BAT


Determinants	Odds ratio	Changeabilitya	Category	Target groupb

Demographic

Age >40 years	2.65	-	Not applicable	Not applicable

Chronic illness	3.37	-	Not applicable	Not applicable

Behavioural

Aware of personal risk for influenza infection	2.80	+	Knowledge	2

Aware of risk of infecting patients	2.54	+	Knowledge	2

‘Vaccination reduces risk of infecting patients’	3.68	+	Knowledge	2

‘Vaccination is useful despite the constant flow of visitors’	1.88	+	Knowledge	2

Aware of the contents of the Health Council’s Advice	2.41	+	Knowledge	2

‘HCWsc should get vaccinated to ensure continuity of care’	2.15	+	Common interest	3

‘HCWs should get vaccinated because of their duty to do no harm’	2.22	+	Common interest	3

‘People around me think it is important for me to get vaccinated’	1.74	+/-	Social impact	3

‘I would definitively get vaccinated if it was available at a convenient time’	28.91	+	Organizational	1,2,3


Rank	rs ID	pval	Gene Sym	Gene Name	SNP Function

1.0	rs10018625	0.001536	TAG ERROR	TAG ERROR	unknown, TAG ERROR

2.0	rs1047643	0.001603	FDFT1	Farnesyl-diphosphate farnesyltransferase 1	coding-synon

3.0	rs20541	0.001644	IL13	Interleukin 13	coding-nonsynon

4.0	rs2108622	0.0020374	CYP4F2	Cytochrom P450, family 4, subfamily F, polypeptide 2	coding-nonsynon

5.0	rs3759259	0.002362	STYK1	Protein kinase STYK1	coding-nonsynon

6.0	rs1801133	0.003251	MTHFR	5, 10-methylenetetrahydrofolate reductase (NADPH)	coding-nonsynon

7.0	rs2069456	0.003375	CDK5	Cyclin-dependent kinase 5	intron

8.0	rs1131532	0.005650	TNFSF10	Tumor necrosis factor (ligand) superfamily, member 10	coding-synon

9.0	rs882709	0.005965	SETX	senataxin	coding-nonsynon

10.0	rs4646421	0.007847	CYP1A1	Cytochrome P450, family 1, subfamily A, polypeptide 1	intron

11.0	rs1799969	0.008221	ICAM1	Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor	coding-nonsynon

12.0	rs3822430	0.009157	SRD5A1	Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)	coding-synon

13.0	rs7903344	0.009471	CHUK	Conserved helix-loop-helix ubiquitous kinase	coding-nonsynon

14.0	rs13926	0.011531	TRAP1	TNF receptor-associated protein 1	coding-nonsynon

15.0	rs3172469	0.012006	BCL6	B-cell CCL/lymphoma 6 (zinc finger protein 51)	intron

16.0	rs215101	0.012028	ABCC1	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	intron, TagSNP:ABCC1

17.0	rs2227564	0.012246	PLAU	Plasminogen activator, urokinase	coding-nonsynon

18.0	rs3096057	0.012484	CSF1	Colony stimulating factor 1 (macrophage)	Promoter

19.0	rs6474491	0.013935	STAR	Steriodogenic acute regulator	Promoter

20.0	rs2066471	0.015231	MTHRF	5, 10-methlyenetetrahydrofolate reductase (NADPH)	intron


 	AA-MF	GMP-MF	p

Energy

 kcal/d	2,266 ± 263	2,566 ± 204	0.26

kcal from MF/d	544 ± 100	763 ± 118	0.049

kcal from NF/d	1,722 ± 229	1,802 ± 127	0.77

Protein

 g protein/d	79 ± 4	81 ± 6	0.70

g protein from MF/d	57 ± 5	55 ± 7	0.72

g protein from NF/d	21 ± 2	26 ± 4	0.32

Calcium : phosphorus ratio3

 Ca : P ratio/d	1.06 ± 0.14	1.19 ± 0.17	0.13

Ca : P ratio from MF/d	0.96 ± 0.14	1.22 ± 0.04	0.03

Ca : P ratio from NF/d	0.90 ± 0.27	1.38 ± 0.66	0.28

Vitamin D2

 IU vitamin D/d	630 ± 230	680 ± 167	0.75

IU vitamin D from MF/d	623 ± 182	593 ± 131	0.82

IU vitamin D from NF/d	54 ± 30	60 ± 26	0.81

Calcium2

 mg calcium/d	1,745 ± 274	1,898 ± 270	0.69

mg calcium from MF/d	1,282 ± 240	1,408 ± 264	0.58

mg calcium from NF/d3	416 ± 78	484 ± 76	0.39

Magnesium

 mg magnesium/d	568 ± 62	684 ± 113	0.27

mg magnesium from MF/d	362 ± 68	400 ± 68	0.43

mg magnesium from NF/d	206 ± 30	284 ± 77	0.37

Phosphorus

 mg phosphorus/d	1,836 ± 228	1,749 ± 161	0.62

mg phosphorus from MF/d	1,183 ± 229	1,131 ± 195	0.80

mg phosphorus from NF/d	653 ± 58	618 ± 69	0.70

Potassium

 mg potassium/d	3,249 ± 403	3,699 ± 383	0.40

mg potassium from MF/d	1,100 ± 307	1,388 ± 175	0.39

mg potassium from NF/d	2,149 ± 324	2,311 ± 302	0.70

Sodium

 mg sodium/d2	2,559 ± 298	3,487 ± 334	0.006

mg sodium from MF/d	499 ± 123	1,251 ± 176	0.017

mg sodium from NF/d2	2,060 ± 271	2,236 ± 270	0.48


Category	Male (n = 129)	Female (n = 108)	P-value

Mean (sd)	Mean (sd)

Confidence to undertake endodontic treatment	11.34 (2.65)	09.87 (2.83)	0.001*

Training/Support for undertaking more endodontic treatment in NHS primary dental care	11.33 (2.48)	11.12 (2.41)	0.51

Dissatisfaction with endodontic service access	11.72 (2.25)	12.05 (2.19)	0.051

Acceptability/Support for DwSI services	15.09 (2.05)	15.58 (1.68)	0.047

Interest in training as an endodontic DwSI	3.48 (1.36)	3.51 (1.41)	0.82


Citation	Mosquito Species	Diet Components	Success Rate

1955. Lea et al. [57]	Aedes aegypti, Ae. quadrimaculatus	Skimmed milk with 10% honey.	The authors state that skimmed milk can be a substitute for blood to produce eggs. An. quadrimaculatus was also fed proteose-peptone, liver concentrate, and casein hydrolysate.

1955. Dimond et al. [58]	Aedes aegypti	Mixture of 18 amino acids in 10% honey water.	A low egg number of 5.2 eggs/female is reported

1990. Kogan [56]	Aedes aegypti	Porcine albumin (102 mg/mL), γ-globulin (15 mg/mL), hemoglobin (8 mg/mL), ATP (1 mM), NaCl (5–10 mM), and NaHCO3 (120 mM) in water.	101 ± 6.8 eggs/female

1996. Cosgrove and Wood [59]	Aedes aegypti	Porcine albumin (100 mg/mL), γ-globulin (15 mg/mL), hemoglobin (8 mg/mL), isoleucine (2.5 mg/mL), ATP (1 mM), NaCl (5–10 mM), and NaHCO3 (120 mM) in water.	55.32 ± 4.1 eggs/female. 61.9% hatch rate

1996. Cosgrove and Wood [59]	Aedes aegypti	Bovine serum albumin (100 mg/mL), γ-globulin (30 mg/mL), hemoglobin (8 mg/mL), and ATP (1 mM) in Ringer‘s solution.	64.56 ± 5.1 eggs/female. 54.1% hatch rate. A colony of Ae. aegypti was raised on this diet for more than 25 generations

1996. Griffith and Turner [60]	Culex quinquefasciatus	Soy milk formula (33 mg/mL), γ-globulin (11.5 mg/mL), ovalbumin (76.5 mg/mL), ATP (1 mM), NaCl (150 mM), and NaHCO3 (100 mM) in water. 	116 eggs/female. Colonies were maintained for 6 and 15 generations

2014. Pitts [61]	Aedes albopictus	Bovine serum albumin (200 mg/mL) and ATP (1 mM) in phosphate buffered saline. 	92.2 ± 4.4 eggs/female. 71.8% ± 6.1% hatch rate. Colonies were maintained for 6 generations

2015. Gonzales et al. [32]	Aedes aegypti	Bovine serum albumin (200 mg/mL), ATP (1 mM), and iron (III) chloride (0.5 mg/mL) in Aedes physiological saline. 	66 ± 10.8 eggs/female. 33.06% ± 12.34% hatch rate


Type of services	Quantitative indicators (Survey of female workers)	Qualitative indicators

Hotline	• Frequency of services• Ranking frequent topic of call• Number of calls over time• % of women ever heard about the services• % of women ever used services• Ranking about quality/importance of services	• In-depth information about issues when implementing services from service provider (hotline expert)• In-depth information about relevance, quality and usefulness of services from female workers

Map of health care services providers	• Number of health services provided surveyed and presented in map• % of women ever received map• % of women ever used map to find health care providers• Ranking about quality/importance of services	• In-depth information about relevance, quality and usefulness of services from female workers

SMS	• Frequency of services• Number of SMS developed• Number of SMS sent over time• Major topic of SMS sent• % of women ever heard about the services• % of women ever used services• Ranking about quality/importance of services	• In-depth information about relevance, quality and usefulness of services from female workers


	All tumors	TC	AC	LCNEC

Clinical status at last f/u

Alive without recurrence	35	30	5	0

Alive with recurrence	2	0	1	1

Alive, unknown	7	6	0	1

Died with disease	8	0	1	7

Died of other causes	2	2	0	0

Died, unknown cause	1	1	0	0

Median disease free survival (months)†	NR	NR	35.5	10.1

Hazard ratio		<0.01	0.10	1.00

Confidence interval (95%)		-	0.01-0.57	-

P-value	-	<0.0001	0.0063	-

Mean DFS follow-up (months)	20.2	21.9	21.9	12.0

Median survival (months)	NR	NR	NR	19.7

Hazard ratio		0.06	0.08	1.00

Confidence interval (95%)		0.01-0.24	0.00-0.54	-

P-value	-	<0.0001	0.0070	-

Mean OS follow-up (months)	29.6	31.4	34.3	18.3


Drug	Route	IC50(μM)	Max serum level (μM)	Elimination half life	Efficacy	Mode of action

Aclarubicin	IV	0.94	0.34	13.3 hrs	-122.30	Topoisomerase I and II inhibitor

Actinomycin D	IV	0.38	0.02-0.08	36 hrs	-112.51	Inhibitors of DNA synthesis

Bortezomib	IV	0.34	0.16-0.31	9-15 hrs	-77.11	Proteasome inhibitor;

Carboquone	PO/IV	0.75	0.62-0.74 (200-240 ng/mL)	0.5 hrs	-119.79	Alkylating agents

Ciclopirox	Topical	0.64	N/A - topical only	2.2 hrs in rabbits	-61.11	Chelation of polyvalent metal cations

Deslanoside	 	0.34	0.16	51 hrs	-110.35	Na+/K + ATPase inhibition;

Digitoxin	IV	0.08	0.05-0.2	4-9 days	-109.13	Na+/K + ATPase inhibition;

Digoxin	PO/IV	0.19	0.003	36-48 hrs	-111.40	Na+/K + ATPase inhibition;

Ecteinascidin	IV	0.01	Up to 0.05	50-180 hrs	-116.82	Disruption of DNA strand

Homoharringtonine	SQ	0.21	0.176	9.3 hrs	-125.33	Protein synthesis inhibitor

Lanatoside A	IV/PO	0.19	N/A	N/A	-114.10	Na+/K + ATPase inhibition;

Lanatoside C	IV/PO	0.3	N/A	N/A	-117.82	Na+/K + ATPase inhibition;

Methotrexate	PO/IV	0.02	10-100	8-15 hrs	-74.91	DHFR inhibitor

Metildigoxin	PO/IV	0.24	N/A	N/A	-110.90	Na+/K + ATPase inhibition;

Niclosamide	PO/IV	0.27	N/A	N/A	-94.29	Uncouple oxidative phosphorylation

Ouabain	IV	0.08	0.128	18 hrs	-110.64	Na+/K + ATPase inhibition;

Plicamycin	IV	0.94	0.6 μM	10.5 hrs	-117.62	RNA synthesis inhibitor;

Proscillaridin A	IV/PO	0.01	0.019 (IV); 0.0019 (PO)	23-33 hrs	-110.55	Na+/K + ATPase inhibition;

Pyrimethamine	PO/IV	0.75	8.04	140-190 hrs	-81.43	DHFR inhibitor

Rotenone	N/A	0.75	N/A	N/A	-69.22	Electron transport chain in mitochondria interference

Trimetrexate glucuronate	IV	0.01	N/A	11-16 hrs	-80.39	DHFR inhibitor


Dataset	Description	Updated	Genes	Reference

hg18rpa	Protein-coding genes on autosomal chromosomes (based on human genome hg18 and RefSeq genes)	2011	18,166	[35]

HI	Recombination hotspots intersected genes	2010	1,156	-

MI	Recombination middle spots intersected genes	2010	1,481	-

CI	Recombination cold spots intersected genes	2010	1,594	-

HK	Housekeeping genes	2011	1,974	[36]

SPD	Genes encoding secreted proteins	2010	1,667	[37]

TiGER	Tissue-specific genes	2008	4,710	[38]

DGD	Duplicated genes	2012	4,393	[16]

AGE	Genes classified by different evolutionary age	2011	16,418	[17]

OMIM	Mendelian disorder associated genes in human	2012	2,624	[39]

MD	Mendelian Disease Genes (at least one mutation in the particular gene is causative of the disease)	2011	1,629	[21]

CGC	Genes with mutations have been causally implicated in cancer	2011	424	[23]

TICdb	Reciprocal translocation associated genes in human tumours	2008	240	[40]

dbCRID	Chromosomal rearrangement associated genes in human diseases	2010	401	[22]

InteCR	Integrated chromosomal rearrangement associated genes in human diseases (Combined of dbCRID, TICdb and CGC genes)	2012	614	-


	Inoculated andContacts vs.Controls	Inoculated vs.Contacts	Carriers vs.Non-Carriers

SAA	<0.0001***	0.61	0.49

IFN	<0.0001***	0.43	0.27

Haptoglobin	<0.0001***	0.04*	0.015*


Gene name	Sequence (5’–3’)

β-actin	Sense: TCTTGGGTATGGAGTCCTGAntisense: TAGAAGCATTTGCGGTGG

FGA	Sense: GCAGAACAGCATCCAGGAGCAGGAntisense: TCCACCTGGTAATCAAAACTTCTAGCAC

CA2	Sense: CACTGGCACGAGCACTTCAntisense: ACTTCACGCCATCCACAGT

KRT7	Sense: CTGGACGGGTTGTTAAATAntisense: TCCGCTTCGTAGAGAGAT

GRTP1	Sense: GGCTGCTCCAACGCCCACTTAntisense: CGCAACGCCTTCTGCTCTTT

MnSOD	Sense: CTGACCTGCCCTACGACTAntisense: TGGTATGATTGATATGACCC

LOC429524	Sense: GGAGGAAATGCGGCGCTTAGAntisense: GGCTGGACGAGACGCTGTTGA

ATP5A1	Sense: CAGTTTGGGTCTGATTTGGAntisense: AGCTTAGCTTCCGTCTGG

FKBP4	Sense: TACCTCCCAATGCTACGCAntisense: CCTTCGCCTTTCTTACGG

GOT1	Sense: GCACAGACCCTACTCCAGACAntisense: AAGCCCTCGGAGACAAAG

LMNA	Sense: GGGGAACTGGCAGGTGAAGCAntisense: CCTCGTCGTCGTCGTTGATG

PTGDS	Sense: CCGAGGTCTTTTGTTTGAntisense: AGGAGGGGGACTTTGATG

HSPβ1	Sense: CAAACACGAGGAGAAACAAntisense: CGTTTATTCAAGGCACTG

Apo A-I	Sense: TCCGCTTCGTAGAGAGATGTGAntisense: TCAGCGTGTCCAGGTTGTC


Setting	Number of hours	Number of days	Time period

999	170	41	Nov 2008 – Jul 2010

SPA	172	33	Oct 2009 – July 2010

OOH	149	27	Sept 2009 – Aug 2010

Total	491	101	Nov 2008 – Aug 2010


Substance	Mechanism	Cancer Type	Reference

β-asarone	p53/Bcl-2/Bclin-1 and p53/AMPK/mTOR pathways	Glioma cell line (U251)	[161]

Walsuronoid B	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway	Liver cancer (HepG2 and Bel-7402)	[166]

Sulforaphane	Reduction of phosphorylation of Akt and mTOR	Malignant mesothelioma (H-28)	[167]

Physapubescin B	(ROS)-mediated suppression of mTORC1	Colon cancer (HCT116) and cervical cancer (HeLa)	[168]

Fluvastatin	p53/AMPK/mTOR pathway	Lung adenocarcinoma (A549 and SPC-A-1)	[169]

Trichostatin A and Valproic Acid	ROS formation	Pancreatic cancer (Panc1 and PaCa44)	[170]

Cobalt chloride	p53/Bcl-2/Beclin-1 pathway	Malignant glioma (U87-MG)	[162]

Oridonin	AMPK deactivation-mediated GLUT1 downregulation in p53-mutated cells	p53-mutated colorectal cancer cells (HCT-15, COLO205, HCT116, RKO, SW480, and SW620)	[171]

Astemizole-Histamine	ROS formation and p53 phosphorylation, which increased p53-p62 interactions to enhance Beclin-1-independent autophagy	breast cancer (MCF-7)	[172]

Polygonatum odoratum lectin	Up-regulation of miR-15a-3p, which mediated ROS-p53 pathway	human lung adenocarcinoma (A549)	[173]

Trichosanthin	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway,	gastric cancer (MKN-45)	[174]

Honokiol	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway	Glioma (U87 MG)	[175]


	Practice (n=number of participating GPs at commencement)

Organisational Characteristics	Eastvale (n = 5)	Gibson (n = 1)	Frank (n = 4)	Southville (n = 7)	Coopers (n = 7)	West Sanders (n = 9)

Funding Structure

 Privately owned primary care sites	Y	Y	Y	Y

 Corporatised primary care site						Y

 Publicly funded community health centre					Y

Location

 Urban	Y	Y			Y	Y

 Outer Urban				Y

 Regional			Y

Personnel employed in the practice (in total)

 GP(s)	6	2	4	8	8	14

 Practice nurse(s)	2	3	2	4	2	3

 Registrar(s)	1	0	0	0	0	1

 Psychologist(s)	1	1	0	2	1	1

 Practice manager(s)	1	0	1	1	1	1

 Receptionist(s)	6	2	3	10	5	7

 Other	2	0	2	7	10	0


Variables	Adjusted odds ratio	95% confidence interval	p-value

Therapeutic Self-Care	0.74	0.56, 0.96	0.03

Over age 75	1.01	0.77, 1.34	0.93

Female	0.77	0.63, 0.96	0.02

Polypharmacy	1.11	0.87, 1.44	0.40

Polypharmacy*Therapeutic Self-Care	1.48	1.10, 2.02	0.01

CHESS Scores	1.42	1.14, 1.76	<0.01

Congestive Heart Failure	1.66	1.20, 2.30	<0.01

Alzheimer’s Disease	1.31	1.01, 1.70	0.02

Model Fit Assessment	Chi-Square	DF	p-value

Likelihood Ratio	68.28	10	<0.01

Model Fit Assessment	Association of Predicted Probabilities and Observed Responses

C-index	0.62


			Fold change

SAGE tag	RefSeq accession	Gene ID	Caudal/rostral (SAGE)	Caudal/rostral (RT-qPCR)

gttgttcttccagtcgg	NM_016916	bladder cancer associated protein homolog (human), Blcap	2.68	1.43

gtcatagctgttctgtg	BC025816	EST sequence BC025816	Cs	1.31 (NS)

aagcttgacatttggaa	NM_026187	ankyrin repeat and zinc finger domain containing 1, Ankzf1	Rs	1.17† (NS)

gatacttggaatgacta	NM_007393	actin, beta, cytoplasmic, Actb	-2.63	-1.32

ttggtgaaggaaaaaac	NM_021278	thymosin, beta 4, X chromosome, Tmsb4x	-2.33	-2.13 (NS)


Target gene	Primer name	Nucleotide sequence (5'–3')	Product size (bp)	PCR profile (°C/s)	Reference

Denaturation	Annealing	Extension	Cycles

17 kDa	Rr17k. 1p	TTTACAAAATTCTAAAAACCAT	539	95/30	57/60	72/120	35	[23]

Rr17k. 539n	TCAATTCACAACTTGCCATT

Rr17k. 90p	GCTCTTGCAACTTCTATGTT	450	95/30	57/60	72/120	35

Rr17k. 539n	TCAATTCACAACTTGCCATT

ompA	Rr190k. 71p	TGGCGAATATTTCTCCAAAA	650	95/30	42/35	60/120	35	[23]

Rr190k. 720n	TGCATTTGTATTACCTATTGT

Rr190k. 71p	TGGCGAATATTTCTCCAAAA	532	95/30	48/60	65/120	35

Rr190k. 602n	AGTGCAGCATTCGCTCCCCCT


 Type	Number of cases

Detected	Misreported	Under-reported	Total

Probe	226	4	7	233

DoS	131	14	23	155

R2L	77	12	12	89

U2R	29	12	8	36


Feature of presenting complaint	Study participants (n = 30)

Trauma (%)

 Yes	16 (53.3)

 No	14 (46.7)

Weight-bearing (%)

 Yes	17 (56.7)

 No	13 (43.3)

Side affected (%)

 Right	11 (36.7)

 Left	18 (60.0)

 Both	1 (3.3)

Region affected (%)

 Hip	5 (16.7)

 Thigh	8 (26.7)

 Knee	6 (20.0)

 Lower leg	8 (26.7)

 Ankle	3 (10.0)

Diagnosis (%)

 Soft tissue injury	13 (43.3)

 Irritable hip	9 (30.0)

 Toddler’s fracture	3 (10.0)

 Other	4 (13.3)

 Unknown diagnosis	1 (3.3)


	p-value 	Pearson correlations

Infant age (month) 	0.002 	-0.270

Height at birth (cm) 	0.010 	0.237

Weight at birth (kg) 	0.940 	-0.007

Head circumference at birth (cm) 	0.251 	0.157


Annotation category	Number of annotations

Natural antisense lncRNA	64

Pseudogene	75

Transposable element gene	10

Transposase	46

miRNA primary transcript	4

Hypothetical protein	5

Protein	8

Other	8


Sharing platform	Current users, n = 200n (%)

Do not share data	130	(65.0%)

Tracker support software	70	(35.0%)

Strava	9	(4.5%)

Facebook	7	(3.5%)

Instagram	2	(1.0%)

In person	2	(1.0%)

Twitter	1	(0.5%)

Other	3	(1.5%)

Reasons for sharing on social media

Do not share data on social media	154	(77.0%)

To compete with friends	33	(16.5%)

To share progress	18	(9.0%)

To motivate others	17	(8.5%)

To get encouragement from others	13	(6.5%)

Other	4	(2.0%)


Variable	Opium addicted N=50	Non addicted  N=50	P value

Age Mean±SD	36.00±6.54	35.38±6.7	0.64

BMI Mean±sD	21.96±3.46	24.27±3.85	0.002

Cigarrette smoking No. (%)	37 (77.1)	34 (61)	0.31

Vertebral BMD frequency (%)

Normal	22 (44)	37 (74)	0.002

Osteopenia	28 (56)	13 (26)

Lumbar measurement Mean±SD	0.92±0.12	1.01±0.12	0.001


National policies and guidelines

Recording and Reporting tools

Collaboration and communication between TB and HIV control programmes

Leadership and commitment

Target setting at all levels of the health care system

Human resources: recruitment, training, support, task shifting

Financing

National Partnerships for results

Providing TB and HIV services under one roof


Gene	Primers

ABCG2	Primer1: 5′-TGGCTTAGACTCAAGCACAGC-3′

Primer2: 5′- TGGTCCCTGCTTAGACATCC-3′

MRP1	Primer1: 5′-TGTGGGAAAACACATCTTTGA-3′

Primer2: 5′-CTGTGCGTGACCAAGATCC-3′

MRP2	Primer1: 5′-AGTGAATGACATCTTCACGTTTG-3′

Primer2: 5′-CTTGCAAAGGAGATCAGCAA-3′

MDR1	Primer1: 5′-ACAGAAAGCGAAGCAGTGGT-3′

Primer2: 5′-ATGGTGGTCCGACCT TTTC-3′

CD44	Primer1: 5′-GCCTTGGCTTTGATTCTTGC-3′

Primer2: 5′-TCCACTTGGCTTTCTGTCCTC-3′

HES1	Primer1: 5′-GAAAGATAGCTCGCGGCAT-3′

Primer2: 5′'-GAAGCGGGTCACCTCGTT-3′

Krt15	Primer1: 5′-GCTGCTTGACATAAAGACACG-3′

Primer2: 5′'-ATTGCTGCTGCTACCACCA-3′

Oct-4	Primer1: 5′-GGAAGGTATTCAGCCAAACGACCA-3′

Primer2: 5′'-CTCACTCGGTTCTCGATACTGGTT-3′

Sox2	Primer1: 5′-TTCGATCCCAACTTTCCAT-3′

Primer2: 5′'-ACATGGATTCTCGGCAGAC-3′

GAPDH	Primer1: 5′-GCCGGTGCTGAATATGTC-3′

Primer2: 5′-CTTCTGGGTGGCAGTGAT-3′


Study	Running distance	Running period	OA induced	Method	Effect

Sekiya et al. [5] 2009	30 km	6 weeks	No		Harmful

Siebelt et al. [24] 2011	31.8 km	6 weeks	No		Harmful

Beckett et al. [17] 2012	30 km / 55 km	3 / 6 weeks	No		Harmful

Pap et al. [20] 1998	30 km	12 weeks	Yes	Intracranial self stimulation	Harmful

Siebelt et al. [21] 2014	15 km	6 weeks	Yes	Papain injection	Harmful

Saito et al. 2015	15 km	3 weeks	Yes	MIA 0.1 mg injection	Harmful

Galois et al. [22] 2004	15 km	4 weeks	Yes	ACLT	Beneficial

Cifuentes et al. [23] 2010	15 km	8 weeks	Yes	MIA 1.2 mg injection	Beneficial


	Baseline Value	Source(s)

Input variables

 Chest pain is caused by ACS	0.1	[19-22]

 GP Sensitivity with ECG	0.818	Unpublished data from [8,11-16]

 GP Sensitivity without ECG	0.667	Unpublished data from [8]

 GP Specificity with ECG	0.5	[12-16]

 GP Specificity without ECG	0.3	[17]

 Correctly referred STEMI patients receiving thrombolysis (%)	58.5	[6]

 Relative risk reduction of thrombolytics	0.750	[23,24]

Costs (2007 US$)

 GP visit	1.76	[37]

 ECG	1.93	[39,40,42-44]

 Emergency department visit	3.48	[37]

 Streptokinase	117.00	[38,45]

 Admission	157.55	[37]

 Blood transfusion	107.67	[37]

 Stroke	211.37	[37]

 Annual secondary prevention	16.56	[37,38]


#	Author	Year	Compound	Strain	Dose	Rote	Test	(Model)

1	Nagase et al. 	2002 	TAN-67 	SD 	1-10 mg/kg 	s.c. 	FSS

2	Broom et al. 	2002 	SNC80 	SD 	10-100 mg/kg 	s.c. 	FSS

3	Broom et al. 	2002 	(+) BW373U86 	SD 	1-10 mg/kg 	s.c. 	FSS

4	Saitoh et al. 	2004 	SNC80 	ICR 	0.3-3 mg/kg 	s.c. 	FSS/CSM

5	Torregrossa et al. 	2005 	(+) BW373U86 	SD 	10 mg/kg X 1, 8, 21 days 	s.c. 	FSS

6	Naidu et al. 	2007 	(-) NIH11082 	C57BL6 	8-32 mg/kg 	i.p. 	TST

7	Saitoh et al. 	2008 	SNC80 	Wistar 	1-10 mg/kg X 7 days 	s.c. 	HE 	OB rat model

8	Vergra et al. 	2008 	UFP-512 	Swiss 	0.001-0.1 nmol/0.01-1 mg/kg 	i.c.v./i.p. 	FSS

9			UFP-512 	SD 	0.1-1 mg/kg 	i.p. 	FSS

10	Le Bourdonnec et al. 	2008 	ADL5859 	- 	0.3-3 mg/kg 	p.o. 	FSS

11	Saitoh et al. 	2011 	KNT-127 	ICR 	0.1-1 mg/kg 	s.c. 	FSS

12	Hudzik et al. 	2011 	AZD2327 	SD 	1-10 mg/kg X 4 days 	p.o. 	LH


 	Predictability of Spherical Equivalent*

 	undercorrection <1.0	1.0 to 0.51	±0.5	0.51 to 1.0	overcorrection >1.0	Total

 	WTR

Number	1	9	34	6	0	50

%	2	18	68	12	0	100

 	Oblique

Number	3	8	38	9	0	58

%	5	14	66	16	0	100

 	ATR

Number	1	6	30	7	1	45

%	2	13	67	16	2	100


Y-Intercept (#/cm3)	Weekday	Weekend

Day	Night	Day	Night

Ultrafine 	50 (5)	101 (8)	43 (11)	143 (7)

Fine 	48 (2)	62 (2)	46 (5)	90 (3)


	Haddadi et al.	Huang et al.	Lu &Zoubir	Ours

E(lq)	Lawley	Lawley	Lawley	Lawley

Var(lq)	Multivariate Statistics	Random Matrix	Random Matrix	Lawley

E(Aq)	Lawley	Lawley	Lawley	Lawley

Var(Aq)	- *	-	Random Matrix	Random Matrix


	N	M ± SD

Outcome: Teaching qualitya

 Didactics	499	7.9 ± 1.3

 Learning climate	500	8.4 ± 1.1

 Motivation and enthusiasm	500	8.1 ± 1.3

 Behavior towards patients	488	8.1 ± 1.2

Motivational categoriesb	55 for all

 Intrinsic TM		2.7 ± 0.9

 Identified TM		3.2 ± 0.7

 Introjected TM		0.7 ± 0.8

 External TM		1.5 ± 1.0

 T Amotivation		0.9 ± 0.9

Teaching self-efficacyb	55	2.5 ± 0.5

Situational variablesb	94 for all

 Enough time to prepare lesson		2.1 ± 1.2

 Stress before lesson		2.2 ± 1.1

 Perceived students’ motivation		3.1 ± 0.7

 Perceived students’ competences		2.9 ± 0.8

 Perceived students’ respect		3.6 ± 0.6


Medical	Nursing

Enhanced scopes of practice

• Physicians are allowed to private practice with specific fees during off hours	• Nurses also are allowed to work in the private sector before and after office hours

Producing new types of health workers

• The programmes for production of other paramedics such as medical assistants, laboratory assistants, pharmacists, and physiotherapy assistants are already in place	• Currently, there are a number of nursing and related programmes, such as BSc nursing, postbasic nursing, diploma in nursing, family welfare assistant, community skilled birth assistants, and community health-care providers

Compulsory service in rural area

• Provision of minimum 2 years of services at Union Health Sub-Centre	• The Nursing Personnel Recruitment Rules were developed in 1985, without any provision of compulsory rural services

• Preference to fill vacancies for remote and hard-to-reach areas/health facilities	• Recently, efforts are underway to introduce provision of compulsory services in rural health facilities

• Provision of non-practicing allowance is given to encourage physicians to purely focus on public services

Subsidized education for return of service

• Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention	• Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention


Objection	Primer	Sequences

Murine variable regions of the heavy chain (VH)	VHF	5'-GCTGCCCAACCAGCCATGGCCGAGGTGCAGCTGGTGGAATCGGG-3'

VHR	5'-CGATGGGCCCTTGGTGGAGGCTGCAGAGACAGTGACCAGAGT-3'

Murine variable regions of the light chain (VL)	VkF	5'-GGGCCCAGGCGGCCGAGCTCGATATTTTGCTCACTCAG-3'

VkR	5'-GAAGACAGATGGTGCAGCCACAGTTCGTTTCATTTCCAGTTTGGTCCC-3'

Human constant regions of the heavy chain domain 1 (CH1)	CH1-F	5'-GCCTCCACCAAGGGCCCATCGGTC-3'

dpseq	5'-GATATCAGAAGCGTAGTCCGGAACGTC-3'

Human constant regions of the light chain domain (CL)	HKC-F	5'-CGAACTGTGGCTGCACCATCTGTC-3'

Lead B	5'-AAGCTTGGCCATGGCTGGTTGGGCAGC-3'

Chimeric heavy chain (Fd)	Lead H	5'-CATATGGCTGCCCAACCAGCCATGGCC-3'

dpseq	Ditto

Chimeric light chain	RSF-F	5'-GGATCCGGAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3'

Lead B	Ditto


		Number of participants (% within category)

Country of graduation and current workplace	Rwanda	13 (76%)

Democratic Republic of the Congo	4 (24%)

Completed whole years since graduation	1 year	6 (35%)

2–3 years	6 (35%)

≥ 4 years	5 (29%)

Gender	Male	15 (88%)

Female	2 (12%)

Desired future specialty	General surgery	12 (71%)

Neurosurgery	2 (12%)

Orthopaedics	1 (6%)

Urology	2 (12%)


CME activity	Activity 2	Activity 3

Sample size	n=1237	n=611

Responses to: Practitioners are asked to report drug adverse events:

A. To MedWatch

B. Only when the adverse event is not specified on the drug label

C. Within 30 days of occurrence, as required by law.

D. Voluntarily, if observed within 30 days of the first dose

Correct (A)	698 (56%)	237 (39%)

Incorrect (B)	85 (7%)	53 (9%)

Incorrect (C)	203 (10%)	174 (29%)

Incorrect (D)	243 (20%)	146 (24%)

Correct vs. Predicted	−14%	−31%


Presyn	Postsyn	Type	Conv	Div	# Synapses

MF	Glom	Excitatory	1	20	5000

Glom	GR	Excitatory	4	53	262,400

Glom	GO	Excitatory	40	0.77	4000

GO	GR	Inhibitory	3.23	2120	212,000

GR	GO	Excitatory	2000	3	200,000

GR	PC	Excitatory	65,600	400	26,240,000

IO	PC	Teaching	1	10	400

PC	DCN	Inhibitory	40	5	2,000

DCN (30%)	IO	Inhibitory	0.34	1	14

IO	DCN	Excitatory	1	1,41	50

MF	DCN	Excitatory	12	2.4	600

Total number of synapses	26,926,464


Transporters	Organism	Cells/Tissue	Cargo (proteins) specific to each importin or exportin	Reference

Importin α1	Human	ROS 17/2.8, UMR-106, MC3T3-E1, and SaOS-2	Type 1 parathyroid hormone receptor	[62]

Importin α2	Human	HuT-78 cells	GATA-3	[63]

Importin α3	Human	A5A9 lung cells, human Bronchial smooth muscle cells	NF-κB p50/p65	[25, 50]

Importin α3	Mouse	Mouse lung tissue	NF-κB p65	[11]

Importin α4	Human	A5A9 lung cells	NF-κB p50/p65	[25]

Importin α5	Human	COS-1HepG2HuH7 hepatoma cells	STAT3 STAT1-STAT2	[45] [43]

Importin β1	Human	HEK293HUVECC58CO57HeLa	PRPF31NF-κBCREBPTHrPSRY/SOX-9Cyclin B1NFAT	[64–69][33][68]

Importin β1	Mouse	Sf9	NFAT	[69]

Importin β2	Human	HeLa	HPV16E6 oncoprotein	[70]

Importin β3	Human	HeLa	c-JunRibosomal proteins	[71, 72]

Importin 4	Human	HeLa	Vitamin D receptorHIF1-α	[73, 74]

Importin 5	Human	HeLa	c-Jun	[70]

Importin 7	Human	HeLa	c-JunHistone H1CREBSMAD3Glucocorticoid receptor	[71][75, 76][33][48][55]

Importin 8	Human	HaCaTCOS-1	SMADsSignal recognition particle protein 19	[76, 77]

Importin 9	Human	HeLa	c-JunPP2A (PR65)	[71][78]

Importin 11	Human	BHK	L12UbcM2	[79, 80]

Importin 13	Human	HeLaAirway epithelial cells	c-JunGlucocorticoid receptor	[71] [57]

Importin α/β	Human	HTCMCF-7	HIV-1 integraseP53	[81, 82]

Exportin 1	Human	NIH-3H3HeLa	Cyclin D1IκBNFAT	[14, 26, 83, 84]

Exportin 4	Mouse	HeLa	elF-5A	[15]

Exportin 5	Human	BHK	Staufen2	[85]

Exportin 6	Human	 	Actin	[86]

Exportin 7	Human	HeLaBHK	P50RhoGAP	[87]

Exportin t	Human	HeLa	tRNA	[72, 88]


Metric	Target Performance

HC	Communication latency and energy consumption reduction (indirectly)

ETX	Reduction of required frame retransmissions

RE	Expansion of network lifetime

PFI	Reduction of network-layer losses

ETT	Assignment of weights to the individual links

WCETT	Focus on fixed nodes of local networks


Variable	Perc. difference (with - without OB)	Difference (with - without OB)	t-stats

Hourly Revenue (Eur)	15.4	6.9	2.76

Waiting time (Min)	3.66	6.2	0.34

Idle time (Min)	−1.42	−9.1	−1.33

Overtime (Min)	4.05	10	0.3

Number of days with OB	112

of days without OB	62


Task	Search	Share	Read	Repeat	Comp man	Comp auto	Query	Analyse	Browse	Populate

Importance	Low	Med	Med	High	Low	High	Low	Low	Low	Med


 	Proteinuria negative (n = 13)	Proteinuria positive (n = 67)	p value

 	Median	(min–max)	IQR	Median	(min–max)	IQR

*Systolic blood pressure	117	103–136	20	126	95–184	16	0,11

*Diastolic blood pressure	77	64–94	10	74	57–98	10	0,13

*Pulse pressure 	41	26–51	9	52	32–78	13	0,01

*Mean aortic pressure	100	73–120	13,5	100	70–133	17	0,24

Aortic distensibility	2,93	1,56–14,40	3,70	2,44	0,32–11,20	1,98	0,14

Aortic systolic diameter (mm)	30,61	26,55–38,31	5,60	33,11	25,81–48,16	6,30	0,01

Aortic diastolic diameter (mm)	29,18	26,10–37,71	5,84	32,78	25,46–47,06	6,62	0,008


Feeding model*	Time of measurement	Reference

	2 h	4, 5, or 6 h	24 h

MCH-INDUCED HYPERPHAGIA IN RAT

Male Sprague-Dawley		−90%		Takekawa et al. (2002)

Male Sprague-Dawley	−72%			Moriya et al. (2009)

Male Sprague-Dawley	−75%	−75%		Nagasaki et al. (2009)

Male Wistar	−70%			Borowsky et al. (2002)

FASTING-INDUCED FEEDING

Male Wistar rats	−35%	−30%	−25%	Huang et al. (2005)

Mice (strain and gender unknown)	−80%	−40%		Balavoine et al. (2007)

DIO male C57BL/6NCrl:BR mice	−35%	−32%	−22%	McBriar et al. (2006)

DIO mice (strain and gender unknown)		−17%	−14%	Palani et al. (2005)

DIO mice (strain and gender unknown)	−12%	−20%	−9%	Sasikumar et al. (2006)

SPONTANEOUS FEEDING

Male Sprague-Dawley rats			−30%	Kamata et al. (2011)

Female KKAy mice	−63%			Kamata et al. (2011)

DIO C57BL/6J mice (gender unknown)			−19%	Haga et al. (2011)

DIO mice (strain and gender unknown)			−21%	Xu et al. (2006)

DIO male F344/Jcl rats			−30%	Kasai et al. (2012)

DIO male F344/Jcl rats		−28%		Kasai et al. (2011)

DIO male Sprague-Dawley rats			−31%	Kowalski and Sasikumar (2007)

Male Sprague-Dawley rats, ingestion of condensed milk#	−45%			Borowsky et al. (2002)


	Number of ACT	% first-line treatment

Benin	95	83.2

DRC	131	67.9

Madagascar	83	76.9

Nigeria	171	88.1

Uganda	360	100.0

Zambia	380	99.5


	Bone 1	Bone 2	Bone 3	Bone 4	Bone 5	Bone 6	Bone 7

Bone 1	-	NS	NS	NS	S	NS	NS

Bone 2	NS	-	NS	NS	S	NS	NS

Bone 3	NS	NS	-	NS	S	NS	NS

Bone 4	NS	NS	NS	-	NS	NS	NS

Bone 5	S	S	S	NS	-	S	NS

Bone 6	NS	NS	NS	NS	S	-	NS

Bone 7	NS	NS	NS	NS	NS	NS	-


Variables	UC (N = 181)

Sex

 Male	107 (59.1%)

Age at UC diagnosis (years), median (IQR)	35.8 (26.1–47.8)

Age at FC level measurement (years), median (IQR)	40.5 (29.2–53.8)

Disease duration before FC level measurement (months), median (IQR)	18.4 (1.9–59.5)

Maximum extent of UC

 Proctitis	33 (18.2%)

 Left-sided colitis	47 (26.0%)

 Extensive colitis	101 (55.8%)

Disease severity of UC

 Clinical remission (Mayo score 0-2)	17 (9.4%)

 Mild activity (Mayo score 3-5)	48 (26.5%)

 Moderate activity (Mayo score 6-10)	98 (54.1%)

 Severe activity (Mayo score 11-12)	18 (10.0%)

Smoking status at UC diagnosis

 Never smoker	100 (55.2%)

 Former smoker	47 (26.0%)

 Current smoker	34 (18.8%)

Family history of IBD

 No family history	171 (94.5%)

 First-degree relative	9 (5.0%)

 Second-degree relative	1 (0.5%)

History of medication use at FC level measurement

 Oral 5-ASA	154 (85.1%)

 Topical 5-ASA	116 (64.1%)

 Topical steroids	32 (17.7%)

 Systemic corticosteroids	124 (68.5%)

 Thiopurines	58 (32.0%)

 Cyclosporine	4 (2.2%)

 Anti-TNF agents	30 (16.6%)

FC level (mg/kg), median (IQR)	1518.0 (360.0–4205.0)

Hematocrit value (%), median (IQR)	37.7 (32.8–42.0)

Serum albumin level (g/dL), median (IQR)	3.7 (2.9–4.0)

Erythrocyte sedimentation rate (mm/h), median (IQR)	26.0 (11.5–44.5)

White blood cell count (×103 /uL), median (IQR)	7.1 (5.6–9.5)

Platelet count (×103 /uL), median (IQR)	300.0 (242.0–379.0)

C-reactive protein level (mg/L), median (IQR)	0.41 (0.10–2.37)

Partial Mayo score, median (IQR)	5 (2–6.5)

Mayo endoscopic subscore, median (IQR)	3 (2–3)

Mayo score, median (IQR)	6 (3–8)

UCEIS, median (IQR)	4 (3–6)


Authors (year), country	Participants	Tool (cut-off if provided)	Results

Burch et al. (2008) [63], South AfricaRisk of bias: High	790	MEWS	Hospital admissionMEWS 0–2 (ref)MEWS 3–4: RR 1.3 (95% CI 1.1 to 1.6)MEWS ≥5: RR 1.7 (95% CI 1.5 to 2.0)In-hospital mortalityMEWS 0–2 (ref)MEWS 3–4: RR 2.8 (95% CI 1.7 to 4.8)MEWS ≥5: RR 4.6 (95% CI 2.7 to 7.8)

Correia et al. (2014) [55], PortugalRisk of bias: Unclear	65	EWS	Length of hospital stay & MortalityScore at 24 h and 12 h seemed to predict both length of stay and mortality (p < 0.05). The EWS would have increased early medical attention by 40% if a threshold of ≥3 was used.

Dundar et al. (2015) [41], TurkeyRisk of bias: Low	671	MEWSVIEWS	HospitalisationMEWS (≥3): AUROC 0.73 (95% CI 0.69–0.77)VIEWS (≥6): AUROC 0.76 (95% CI 0.72–0.79)In-hospital mortalityMEWS (≥4): AUROC 0.89 (95% CI 0.84–0.94)VIEWS (≥8): AUROC 0.90 (95% CI 0.86–0.94)

Eick et al. (2015) [42], GermanyRisk of bias: Low	5730	MEWS	In-hospital mortalityAUROC: 0.71 (0.67–0.75; p < 0.001)

Graham et al. (2007) [56], Hong KongRisk of bias: Unclear (Conference abstract)	413	MEWS (>4)	In-hospital mortalityOR 8.3 (95% CI 1.1–60.4), p = 0.013ED re-attendance within 48 hOR 45.2 (95% CI 3.4–568.9), p < 0.0001

Heitz et al. (2010) [43], USARisk of bias: Low	280	MEWS Max (≥4)MEWS plus	Need for higher level of care or mortality within 24 hMEWS Max: AUROC 0.73 (95% CI, 0.66–0.79)MEWS Plus: AUROC 0.76 (95% CI, 0.69–0.82)

Junhasavasdiku et al. (2012) [58], ThailandRisk of bias: Unclear	381	MEWS	MortalityMEWS at ED was associated with mortality (p < 0.001)

Naidoo et al. (2014) [62], South AfricaRisk of bias: High	265	TEWS	Discharge within 24 h of admission, admission to a ward, admission to an intensive care unit (ICU), and death in hospital.TEWS <7: 53.7% discharged; no admitted to ICU; none died.TEWS ≥7: 18.7% discharged; 3 admitted to ICU; 4 died

Olsson et al. (2003) [33], SwedenRisk of bias: Low	1027	APACHE IIRAPSREMS	MortalityREMS: AUROC: 0.91 ± 0.02RAPS: AUROC: 0.87 ± 0.02APACHE II: AUROC: 0.90 ± 0.02

Olsson et al. (2004) [34], SwedenRisk of bias: Low	11,751	RAPSREMS	MortalityRAPS: AUROC: 0.65 ± 0.02REMS: AUROC: 0.85 ± 0.01

Subbe et al. (2006) [50], UKRisk of bias: Low	(a) 53 unselected; (b): 49 ICU admission; (c): 49 ED admission, transferred to ward then ICU	MEWS (>2)ASSIST (>3)MET (=1)MTS (orange or red)	Patients identified as critically ill (at risk of deterioration)MTS: Sensitivity: (a) 15%; (b) 96%; (c) 65%MEWS: Sensitivity (a): 8%; (b) 77%; (c) 55%ASSIST: Sensitivity (a): 0%; (b) 22%; (c) 16%MET: Sensitivity (a) 0%; (b) 2%; (c) 7%

Wang et al. (2016) [60], TaiwanRisk of bias: Unclear	99	CCIMEWS	Survival to dischargeCCI: Adjusted OR 0.57 (95% CI 0.38–0.84); p = 0.005Peri-arrest MEWS: Adjusted OR 0.77 (95% CI 0.60–0.97); p = 0.028


Models (Prevent/Treatment)	Antioxidant/Plants	Effects	Dose (Dose-Effect)	Bioactive Compounds	References

Diabetic rats fed on a high fat thermolyzed diet (Prevent)	Omega 3-polyunsaturated fatty acids	↑ SOD, CAT; ↓ triglycerides, non-esterified fatty acid, lipoperoxidation	3.0% in diet	Omega 3-polyunsaturated fatty acids	[108]

Mice fed with high-fat diet (Prevent and treatment)	Moringa oleifera leaves; haw pectic oligosaccharide; Thymbra spicata	↑ GSH; ↓ ALT, AST, ALP, lipid peroxidation	50, 150 and 300 mg/kg b.w. (No dose–effect)	Haw pectic oligosaccharide	[109,110,111]

Liver damage in diet-induced atherosclerotic rats (Prevent)	Tulbaghia violacea rhizomes	↓ LDH, AST, ALT, ALP, bilirubin antioxidation	100 mg/kg b.w.		[112]

Rabbits with high-fat diet (Prevent)	Apolipoprotein A–I	↑ SOD, GSH-Px; ↓ iNOS, MDA	15 mg/kg b.w.		[113]

WeRats fed a high-fat diet (Prevent)	Black cabbage sprout	↑ SOD, CAT, NADPH, GSH-Px, GRD GST	250 and 500 mg/kg b.w. (Dose–effect)		[114]


Questions for nurse practitioners	Questions for senior doctors and nurses

1. How would you describe your role?	1. What is your understanding of the role of the NP?

2. How is the role of a Nurse Practitioner (NP) different from that of doctors and other nurses?	2. What do you perceive is the impact of the NP role on the delivery of care?

− What is the impact of the NP on the delivery of care?	3. How do you think the role of the NP influences the roles of doctors and nurses?

3. Do you think that the roles of existing Emergency Department (ED) clinicians have changed as a result of the NP role?	4. What are the mechanisms that determine the role of the NP?

4. Do you think the roles of NPs would differ at other sites?	5. What is your view on the overlap between NP roles and those of doctors?

− Why do you think they would differ? (e.g. due to ICT, casemix, culture etc.)

− What are the mechanisms which determine the role of the NP? For example, what factors lead to these differences across sites?

5. What is your view on the overlap between NP roles and those of doctors?


Demographic characteristics	Consented to biobanking (n = 2,100)	Refused or withdrew (n = 75)	p-Value

Father’s age; mean (SD)	39.1 (38.8–39.5)	41.3 (39.6–42.9)	0.034

Mother’s age; mean (SD)	33.1 (32.9–33.5)	34.8 (33.1–36.5)	0.056

Mother’s level of education

Before or finished primary school	468 (22.3%)	7 (9.3%)	0.0001

Finished preparatory, secondary, or technical school	912 (43.4%)	23 (30.7%)

Education higher than high school	720 (34.3%)	45 (60%)

Father’s level of education

Before or finished primary school	411 (19.6%)	5 (6.8%)	0.001

Finished preparatory, secondary, or technical school	948 (4.1%)	24 (32.9%)

Education higher than high school	741 (35.3%)	44 (60.3%)

Residency

Metropolitan Cairo	818 (39%)	35 (46.7%)	0.5

Lower Egypt and Delta (except coastal governorates)	598 (28.5%)	18 (24%)

Coastal governorates	289 (13.8%)	11 (14.7%)

Upper Egypt	255 (12.1%)	5 (6.7%)

Suez Canal	78 (3.7%)	4 (5.3%)

Outside Egypt	62 (3%)	2 (4.3%)

Population distribution

Rural	817 (38.9%)	22 (27.7%)	0.077

Urban	1,283 (61.1%)	53 (70.7%)


	Splenic aspirate parasitologic result	Total

Negative	Positive

rK39 ICT strip test

 Negative	5	7	12

 Positive	13	37	50

Total	18	44	62


var gene typea	Genome	Geographic origin	Binding phenotype	No. of potential thrombin cleavage sites byb:	No. of potential thrombin cleavage sites with sequenceb:	Presence ofc:	Thrombin cleavage

CIDR1	Other	Prosper	Peptide Cutter	PR	PRXXR	DBLδ1	KPRGPA	GLGRSL

IT4var06 (DC8)	IT4/FCR3	Southeast Asia	EPCR	?	0	11	7	1d	Yes	No	No	NDe

IT4var19 (DC8)	IT4/FCR3	Southeast Asia	EPCR	?	0	0	7	1d	Yes	Yes	Yes	Yes

IT4var20 (DC8)	IT4/FCR3	Southeast Asia	EPCR	?	0	1	7	0	Yes	No	No	ND

IT4var32b (DC8)	IT4/FCR3	Southeast Asia	EPCR	?	0	0	7	1d	Yes	Yes	Yes	ND

DD2var47 (DC8)	DD2	Southeast Asia	EPCR	?	0	1	6	0	Yes	No	No	ND

IGHvar19 (DC8)	IGH	India	EPCR	?	0	0	6	1d	Yes	No	No	ND

RAJ116var08 (DC8)	RAJ116	India	EPCR	?	0	0	4	0	No	No	No	ND

PFCLINvar30 (DC8)	PFCLIN	Africa	EPCR	?	0	0	4	0	No	No	No	ND

PFD0020c (DC8)	3D7	Unknown	EPCR	?	0	2	10	2 (1d)	Yes	No	No	ND

PF08_0140 (DC8)	3D7	Unknown	EPCR	?	1	1	7	0	Yes	No	No	ND

RAJ116var11 (DC8)	RAJ116	India	EPCR	?	0	0	6	1d	Yes	No	No	ND

PFCLINvar31 (DC8)	PFCLIN	Africa	EPCR	?	2	1	6	1	No	No	No	ND

MAL6P1.316 (DC8)	3D7	Unknown	EPCR	?	0	1	6	0	No	No	No	ND

IT4var01	IT4/FCR3	Southeast Asia	CD36	ICAM-1	0	1	3	0	No	No	No	No

IT4var11	IT4/FCR3	Southeast Asia	CD36	?	0	0	3	1d	Yes	No	No	Yes

IT4var14	IT4/FCR3	Southeast Asia	CD36	ICAM-1	0	0	7	1d	Yes	No	No	ND

IT4var16	IT4/FCR3	Southeast Asia	CD36	ICAM-1	1	2	4	1d	Yes	No	No	ND

IT4var31	IT4/FCR3	Southeast Asia	CD36	ICAM-1	0	0	3	1	No	No	No	ND

IT4var33	IT4/FCR3	Southeast Asia	CD36	?	1	1	2	1d	Yes	No	No	ND

IT4var39	IT4/FCR3	Southeast Asia	CD36	?	0	0	3	1d	Yes	No	No	ND

IT4var44	IT4/FCR3	Southeast Asia	CD36	?	0	0	4	1d	Yes	No	No	ND

IT4var07	IT4/FCR3	Southeast Asia	EPCR	ICAM-1	0	3	3	1d	Yes	No	Yes	Yes

HB3var03	HB3	Central America	EPCR	ICAM-1	0	0	5	1	No	No	No	No

PFD1235wD4	3D7	Unknown	EPCR	ICAM-1	1	1	8	2 (1d)	Yes	No	No	ND

IT4var02	IT4/FCR3	Southeast Asia	?	PECAM-1	0	0	8	1	No	No	No	ND

PF11_0008	3D7	Unknown	?	PECAM-1	0	0	8	1	No	No	No	ND

PF13_0003	3D7	Unknown	?	Rosette	1	0	10	1	No	No	No	ND

HB3var06	HB3	Central America	?	Rosette	0	0	6	0	No	No	No	ND

IT4var09	IT4/FCR3	Southeast Asia	EPCR	Rosette	0	0	4	1d	Yes	No	No	ND

IT4var60	IT4/FCR3	Southeast Asia	?	Rosette	1	0	6	0	No	No	No	ND

Total (n = 30)					8	26	170	23	18	2	3	3/5


Reference material (Certified or recommended values)	Matrix	Recovery rate

NIST 1643e (60.45±0.72 ppb)	Water	93 to 102%

NIST 1568a (290±30 ppb)	Poultry feed/Excreta	91 to 99%

Arsenic standard (20 ppb)	Egg	89 to 97%


 	Conventional group	Cocktail group	P

Mean dosage (mg) a	 	 	N/A

- Meperidine	58.33 ± 24.46	25

- Midazolam	6.81 ± 2.12	2.5

- Propofol	0	172.08 ± 92.15

Dosage (mg/kg/hr) a	 	 	N/A

- Meperidine	2.42 ± 2.58	1.06 ± 0.60

- Midazolam	0.29 ± 0.36	0.11 ± 0.06

- Propofol	0	6.18 ± 3.0

Indications for ERCP	 	 	0.621

- CBD stone	51 (50.0%)	53 (51.5%)

- Benign biliary stricture	7 (6.9%)	10 (9.7%)

- Malignant biliary stricture	28 (27.4%)	20 (19.4%)

- Pancreatic therapy	5 (4.9%)	8 (7.8%)

- Others	11 (10.8%)	12 (11.6)

Time to intubation (min) a	3.10 ± 1.86	3.68 ± 2.38	0.053

Duration (min) a	31.60 ± 17.56	27.88 ±14.38	0.099


Characteristics	Whole cohort (n = 5685)

Women (%)	2782 (50.6)

Age (years)	43.7 ± 0.4

Race/ethnicity (%)

 Non-Hispanic whites	2898 (73.5)

 Non-Hispanic blacks	1085 (9.4)

 Mexican Americans	1021 (7.8)

 Others	681 (9.3)

Education categories (%)

 Below high school	1409 (16.1)

 High school	1391 (24.3)

 Above high school	2885 (59.5)

Smoking (%)

 Never smoker	3045 (52.9)

 Former smoker	1284 (22.9)

 Current smoker	1356 (24.2)

Current drinker (%)	4056 (76.3)

Moderate physical activity (%)	2741 (54.9)

Body mass index (%)

 Normal weight	1869 (35.2)

 Overweight	2036 (34.6)

 Obese	1780 (30.1)

Depression (%)	348 (5.0)

Systolic blood pressure (mm Hg)	119.7 ± 0.3

C-reactive protein (mg/dL)	0.358 ± 0.011

Total cholesterol (mg/dL)	200.74 ± 0.78

Prediabetes (%)	2058 (31.3)


In vitro	Percentage of CD4+IL-10+ (%)	MFI CD4+IL-10+	iMFI CD4+IL-10+

BALB/c	14·2 ± 1·2	125·0 ± 11·2	1775·0 ± 121·9

CBA	3·3 ± 0·2	82·1 ± 4·6	270·9 ± 15·6


Name	Forward and Revers Primers	Product Size	Comment

Bo 5S IGS	F: ACTAGGATGGGTGACCTCCCG;	484	5S-IGS product size

R: CGCTTAACTGCGGAGTTCTGA

Bo ITS1 and 2	F: CGCGAGAAGTCCACTAAACC;	823	Identify sequence differences

R: ACGTCCGATTTTCAAGCTGG

Bo 45S IGS	F: ATTCAGCCCTTTGTCGCTAA;	variable	45S-IGS product size

R: ATGACTACTGGCAGGATCAACCAG

IGS inter-D	ATCGTGTAGGACCGAGAAGT		D type intergenic

IGS inter-CEF	GGTAGGCACAAAAGGAATGC		C, E and F type intergenic


Variable of Interest		n	Mean	Standard Deviation	Notes

Age (years)		344	61.8	7.6

Age of menarche (years)		335	13.3	1.7	9 could not recall the age of menarche

Age of menopause (years)		327	49.9	5.8	17 had not reached menopause

Years since menopause (years)		327	11.9	9.4

Weight (kg)		344	60.5	11.3

Height (cm)		344	153.7	5.7

BMI (kg/m2)		344	25.7	4.7

Body fat percentage (%)		344	36.2	7.0

Speed of sound (m/s)		344	1536.0	28.6

Broadband attenuation of sound (dB/MHz)		344	112.4	11.7

Stiffness index		344	84.8	14.5

T-score		344	−0.7	1.4

Total MET		344	2922.0	2046.8

Number of children (n)		344	2.9	1.8

		n	%

Ethnicity	Chinese 	119	34.6

Malay 	197	57.3

Indian	28	8.1

Menopause status	Natural menopause	274	79.7

Menopause due to surgery	41	11.9

Menopause due to drugs	12	3.5

Perimenopausal	17	5

Education level	No formal education	17	4.9

Primary school	60	17.4

Secondary school	168	48.8

Certificate	31	9

Diploma	37	10.8

Degree	23	6.7

Postgraduate	8	2.3

Cigarette smoking status	Non-smoker	335	97.4

Current smoker	8	2.3

Ex-smoker	1	0.3

Alcohol drinking 	Non-drinker	336	97.7

Current drinker	7	2.0

Ex-drinker	1	0.3

Milk drinking	Non-drinker	173	50.3

Drinker	171	49.7

Coffee drinking 	Non-drinker	146	42.4

Current drinker	197	57.3

Ex-drinker	1	0.3

Physical activity status 	Inactive	15	4.4

Minimally active	193	56.1

HEPA active	136	39.5


SPARQL Query	Note

SELECT DISTINCT ?label ?definitionContent ?ontologyId ?termId	To extract the definition and its metadata for a specific ICD category, A19 – Miliary tuberculosis

 { GRAPH <http://who.int/icd>

{ <http://who.int/icd#A19> <http://who.int/icd#definitionPrefilled> ?prefilledDefinition .

<http://who.int/icd#A19> rdfs:label ?label .

?prefilledDefinition <http://who.int/icd#label> ?definitionContent;

<http://who.int/icd#ontologyId> ?ontologyId;

<http://who.int/icd#termId> ?termId;

}}


Disease	Protein Defect	iNKT Cells	Type II NKT Cells	iNKT Cell Subsets

Gaucher	β-glucosidase (Glucocerebrosidase)	= [13]	↑ (glucosylsphingosine-specific) [13]	ND

Fabry	α-galactosidase A	= [71]	ND	↓ CD4+ iNKT cells [71]

NPC	NPC1	= [70]	ND	No alterations in CD4+ iNKT cells [70]


Properties	Rejuvenator A	Rejuvenator B	Test Method

Form	Liquid	Liquid

Color	pink	Brown

pH	4.8	5.6	pH test paper

Viscosity (25 °C), SFS	40	15	ASTM D-244

Solute component [wt %]	65	60	ASTM D-244

Regeneration component [wt %]	8	8	ASTM D-2006-70

Asphaltene component [wt %]	0.4	0.75


Phage density	Bacterial density	Implication

High	High	Low adsorption rate or partial bacterial refuge, poor control of bacteria. Gives insight to failure

High	Low	Not sustainable – a possible transitory step following successful control of bacteria, before phage densities have equilibrated

Low	High	Phage unable to replicate adequately; possible genetic resistance of bacteria or inaccessible refuge

Low	Low	Treatment success


 	Sango and Daiya

 	Within reach	Out of reach	χ2(1)

Robin and Daiya

Within reach	32	62	0.92

Out of reach	114	174

Koyuki and Daiya

Within reach	32	30	6.12*

Out of reach	101	189

Cherry and Daiya

Within reach	9	26	2.84

Out of reach	120	177

Chelsea and Daiya

Within reach	7	45	16.39**

Out of reach	107	139

Judy and Daiya

Within reach	13	19	0.16

Out of reach	117	199


Bands analyzed	Proteins detected	Database accession number	MOWSE score	Number of unique peptide identified	Sequence coverage, %	emPAI value

1	HoxF NAD-reducing hydrogenase diaphorase moiety large subunit [R. eutropha H16]	gi|38637753	4562	142	81	61.43

2	HoxH NAD-reducing hydrogenase moiety large subunit [R. eutropha H16]	gi|38637756	3401	112	71	48.36

3	HoxU NAD-reducing hydrogenase diaphorase moiety small subunit [R. eutropha H16]	gi|38637754	1692	61	87	194.61

4	HoxY NAD-reducing hydrogenase moiety small subunit [R. eutropha H16]	gi|32527093	474	18	61	7.91

5	HoxI [R. eutropha H16]	gi|38637758	2876	96	73	346.06


Subcategories of DRPs	Number of DRPs	%	resolved

Doctors (N = 272)

 Unnecessary therapy/No clinical indication	13	92.3%	(12/13)

 Untreated indication	162	71.6%	(116/162)

Non reconciled medications	146	72.6%	(106/146)

 Inappropriate duration	4	75.0%	(3/4)

 Inappropriate dose schedule	11	54.5%	(6/11)

 Dose too high	3	33.3%	(1/3)

 Dose too low	1	0.0%	(0/1)

 Drug-drug interactions	3	100.0%	(3/3)

 Inappropriate/inadequate monitoring	1	0.0%	(0/1)

 Prescription error	18	100.0%	(18/18)

 Manifest side effect, no other cause	7	85.7%	(6/7)

 More cost-effective drug available	3	66.7%	(2/3)

 Deterioration/improvement of disease state	3	66.7%	(2/3)

 Synergistic/preventive drug required and not given	19	63.2%	(12/19)

 Duplication of therapy	10	90.0%	(9/10)

 Prescribed drug not available	4	75.0%	(3/4)

 Avoid contraindications	10	70.0%	(7/10)

Nurses (N = 2)

 Charting error	2	100.0%	(2/2)


	Group V	Group I

	UAI		Univariate	Multivariate OR	UAI		Univariate	Multivariate OR

	Row%	(n)	OR	(95%CI)	Row%	(n)	OR	(95%CI)

<underline>Socio-demographics</underline>

Age groups

 18-29	37.5	(72)	1.00	1.00	54.3	(69)	1.00	---

 ≥30	25.0	(20)	0.56*	0.54(0.29,0.98)*	50.9	(28)	0.87

Number of items showing perceived discrimination against MSM (to the above 3 items)

 0 - 2 discrimination responses	30.1	(63)	1.00	1.00	60.8	(45)	1.00	---

 3 discrimination responses	46.0	(29)	1.98*	2.33(1.28,4.26)**	48.1	(52)	0.60

Best friends supporting their sexual orientation

 No/unaware of one's sexual orientation	25.0	(20)	1.00	1.00	42.5	(34)	1.00	1.00

 Yes	37.5	(72)	1.80*	1.97 (1.07, 3.62)*	61.8	(63)	2.19*	1.94(1.05,3.57)*

Number of friends having MSM behaviors

 A few or none	34.7	(43)	1.00	---	47.9	(67)	1.00	1.00

 All or most of them	33.3	(49)	0.94		71.4	(30)	2.72**	2.38(1.11,5.11)*


Compared organisms	CCMP1545	CCMP1545	RCC299	CCMP1545	O. lucimarinus

(pairs)	RCC299	CCMP2099	CCMP2099	O. lucimarinus	O. RCC809

ID (%)	60	57	57	54	73

Coverage (%)	78	74	77	83	93

Gene fraction (%)	83	62	65	76	88

Ortholog count	8141	5859	6160	5534	6449


	Hbase and Phoenix	Cassandra and Presto

Query 1	Query 2	Query 3	Query 4	Query 1	Query 2	Query 3	Query 4

3 nodes processing speed (s)	48.5	2.32	80.2	78.5	40.1	2	25	13

5 nodes processing speed (s)	27.9	1.79	58	50.5	34.3	1.85	20	10


Comparison	Pearson’s Correlation coefficient	R-squared value

NBME (raw) version V1 EM M4	0.51	0.26

NBME (scaled) version V1 EM M4	0.42	0.18

NBME (raw) version V2 EM M4	0.58	0.30

NBME (scaled) version V2 EM M4	0.41	0.13


Cluster name	Voxels	p	Z-MAX	MNI coordinates (mm)	Anatomical regions

rIPS	2163	1.19E-06	3.82	32, − 72, 40	Right lateral occipital cortex

lIPS	1149	0.0011	3.53	-33, − 42, 41	Left superior parietal lobule, left angular gyrus

rFEF	1117	0.00141	3.52	30, − 2, 62	Right superior frontal gyrus

rSPL	735	0.031	3.28	14, − 71, 55	Right precuneus cortex, right superior parietal lobule


Treatment or procedure	Number of patients	Proportion of patients

Laboratory examinations such as blood samples, urine stick test and cultivation	96	67.6%

Electrocardiography	64	45.1%

Diagnostic radiology procedures	42	29.6%

Medicine administered per orally, suppository or as an ointment	41	28.9%

Intravenous medicine or liquid	38	26.8%

Urinary catheterization	16	11.3%

Telemetry	11	7.7%

None	10	7.1%

Oxygen supplement	6	4.2%

Medicine administered subcutaneously, intramuscular or as an inhalation	6	4.2%

Other	5	3.5%

Invasive procedures	4	2.8%


Step

1.	X μL 125I is added to wobbling reaction vial

2.	250 μL phosphate buffer (0.5 M, pH 7.4) is added

3.	50 μL BoNT-A/ phosphate buffer (=50 μg BoNT-A) is addeda

4.	115-X μL phosphate buffer (0.1 M, pH 6.8) is added to adjust the reaction volume to 215 μL

5.	17.5 μL freshly prepared IODOGEN/acetonitrile solution (2.5 μg/35 μL) is added into the reaction mixture (start of reaction, t = 0)

6.	At t = 45 s, another 17.5 μL IODOGEN/acetonitrile solution (2.5 μg/35 μL) is added

7.	At t = 90 s, 100 μL ascorbic acid solution (25 mg/mL, pH 5.0) is added to stop the reaction and to reduce any formed S-Cl bonds

8.	At t = 4.30 min, 10 μL BSA (50 mg/mL) is addedb

9.	At t = 5.30 min, samples are taken for ITLC for determination of the labelling efficiency

10.	At t = 10 min, 360 μL reaction mixture is transferred to a syringe connected to a filterc

11.	The reaction vial is rinsed by 640 μL phosphate buffer (0.1M, pH 6.8) and also transferred to the syringe connected to the filterc

12.	The combined solution in the syringe is filtered and purified on a PD10 column with ascorbic acid solution (5 mg/mL, pH 5.0) as eluent, collected fractions were 0.5 mL

13.	Fractions with highest amount of 125I-BoNT-A and the highest radiochemical purity are pooled

14.	Samples of the pooled 125I-BoNT-A (fractions 6, 7, 8) are taken for ITLC

15.	Final product is diluted by BSA (1 mg/mL) till a concentration of 1 μg/100 μL and stored at 20°C


Patient	Sex/Age of onset	Mutations (exon)	Phenotype	Kayser-Freicher rings	Serum ceruloplasmin	Serum free copper	24 h urinary copper	AST	ALT	PT

Normal				–	20–35 mg/dL	<15 μg/dL	<60–100 μg	<40 IU/L	<40 IU/L	>70%

Patient 1	Male/8	p.Phe1026Tyr (exon 14),c.2866-2A > G(intron 12)	Hepatic, Neurologic	+	0.0032 mg/dL	49 μg/dL	580 μg	26.82 IU/L	20.1 IU/L	49%

Patient 2	Female/8	p.His251Alafs*19(exon 2),p.Ser105*(exon 2)	Hepatic	+	0.0190 mg/dL	low	150 μg	139.1 IU/L	116.9 IU/L	22%

Patient 3	Male/10	p.Pro868Profs*5(exon 11),p.Ser105*(exon 2)	Hepatic	+	0.0920 mg/dL	low	3639 μg	129.0 IU/L	55.7 IU/L	17%